Causal and Candidate Gene Variants in a Large Cohort of Women with Primary Ovarian

Insufficiency

Gorsi B¹, Hernandez EJ¹, Moore B¹, Moriwaki M², Chow CY³, Coelho E³, Taylor E⁴, Lu C⁴, Walker A⁴, Touraine P⁵, Nelson LM⁶, Cooper AR⁷, Mardis ER⁸, Rajkovic A⁹, Yandell M¹, Welt CK²

¹Utah Center for Genetic Discovery, Department of Human Genetics, University of Utah, Salt Lake City, UT, USA

²Division of Endocrinology, Metabolism and Diabetes, University of Utah, Salt Lake City, UT, USA

³Department of Human Genetics, University of Utah School of Medicine, Salt Lake City, UT, USA

⁴University of Utah School of Medicine, Salt Lake City, UT, USA

⁵Sorbonne Universite, Hôpital Universitaire Pitié Salpêtrière-Charles Foix, Service d'Endocrinologie et

Médecine de la Reproduction, Centre de Maladies Endocriniennes Rares de la Croissance et du

Développement, Centre de Pathologies Gynécologiques Rares, Paris, France

⁶Conover Foundation, McLean, VA, USA

⁷Vios Fertility Institute, St. Louis, MO, USA

⁸Institute for Genomic Medicine, Nationwide Children's Hospital, Ohio State University College of

Medicine, Columbus, OH 43215

⁹Department of Pathology, University of California San Francisco School of Medicine, San Francisco,

CA, 94143 USA

Correspondence to

Corrine Welt

Division of Endocrinology, Metabolism and Diabetes

University of Utah
Eccles Institute of Human Genetics
15 N 2030 E
Salt Lake City, UT 84112
USA
Phone: 801-585-1875
Email: cwelt@genetics.utah.edu
Short Title:
Disclosure: MY is a stock holder or has received stock option awards from Fabric Genomics Inc. BM and
MY have received consulting fees from Fabric Genomics Inc. ARC is a consultant for Ferring and a
scientific advisory board member for INVObioscience and Celmatix.
Author Contributions:
Conception of study CKW, BG
Design of work BG, EJH, MM, CYC
Acquisition of Data LMN, ARC, ERM, AR, PT, AW, MM, EC, CYC
Analysis of data ET, CL, AW, CKW, EJH, BM, BG, MJ, EC, CYC
Drafted and revised AW, MY, CKW, MM, EJH, BG, CYC, BM, MY

All authors approved the final version.

Abstract

A genetic etiology accounts for unexplained primary ovarian insufficiency (POI; amenorrhea with an elevated FSH level). Subjects with POI (n=291) and controls recruited for health in old age or 1000 Genomes (n=233) underwent whole exome or whole genome sequencing. Data were analyzed using a rare variant scoring method and a Bayes factor-based framework for identifying genes harboring pathogenic variants. Candidate heterozygous variants were identified in known genes and genes with functional evidence. Gene sets with increased burden of deleterious alleles included the categories transcription and translation, DNA damage and repair, meiosis and cell division. Variants were found in novel genes from the enhanced categories. Functional evidence supported 7 new risk genes for POI (*USP36, VCP, WDR33, PIWIL3, NPM2, LLGL1* and *BOD1L1*). Aggregating clinical data and genetic risk with a categorical approach may expand the genetic architecture of heterozygous rare gene variants causing risk for POI.

Introduction

Primary ovarian insufficiency (POI) encompasses a continuum from infertility in women with ovarian dysfunction to early menopause¹. The cause of POI remains unknown in the majority of women, making intervention impossible to initiate until it is too late¹.

Data overwhelmingly support a genetic cause in women with POI²⁻⁴. Twin studies estimate heritability from 53-71%²⁻⁴. There is a strong relationship between age at menopause in mothers and daughters, with an odds ratio of 6 (95% confidence intervals 3.4, 10.7) for early menopause in daughters whose mothers had early menopause⁵. In small studies it has been estimated that up to 30% of POI cases are familial⁶. The most common known genetic causes include X chromosome defects, *FMR1* premutations and autoimmune causes¹. Nevertheless, the additive effect of these and known iatrogenic causes explain less than 30% of POI. A remarkable number of new POI-associated genes have been discovered, facilitated by whole exome sequencing (WES) in consanguineous and large families⁷⁻¹⁵. The women in these families typically develop POI before puberty, also termed ovarian dysgenesis. Mutations in the DNA of these women have been identified in genes important for mitochondrial function, meiosis, homologous recombination and DNA damage repair^{7,8,10,12,16}.

The inheritance pattern for POI is not recessive in all cases. Heterozygous mutations in genes such as *eIF4ENIF1* cause POI in women in the mid reproductive years⁹. Recessive gene mutations found to cause POI and primary amenorrhea also cause POI or earlier menopause in heterozygous mothers, demonstrating that dominant and semi-dominant mutations may be causal^{17,18}, with heterozygous damaging variants in known genes or in two or more candidate genes causing POI^{19,20}. One study of POI suggested an additive effect from common variants contributing to age at menopause, with a recent study suggesting that common variation may explain a portion of earlier age at menopause, as low as age 34 years^{21,22}.

Most previous WES analyses in large numbers of women with sporadic POI used a candidate gene approach to identify gene mutations most likely to cause POI. However, a

variant-centric approach has identified novel POI candidate genes^{19,23}. We used an unbiased approach and a new prioritization algorithm (GEM)²⁴⁻²⁶ to identify damaging gene variants in known POI genes. We then used a category-wide association approach to test the hypothesis that additional candidate mutations could be found in clustered gene sets created using known genes and gene candidates from model organisms^{27,28}. We demonstrated a significant enhancement in identified gene sets in women with POI compared to controls. These gene sets revealed additional candidate genes in POI, with seven genes confirmed by functional studies to play a role in oocyte or ovary development. These findings improve our understanding of the genetic architecture of POI, an extremely heterogeneous disorder.

Subjects

All subjects were diagnosed with POI as defined by at least 4 months of amenorrhea and an FSH level in the menopausal range. All women were 18 years or older, and had a 46XX karyotype, and normal *FMR1* repeat number. Subjects (n=35) were recruited in Boston.

Additional subjects were recruited from the Partners Biobank (n=63). A second cohort (n=98) was recruited at the National Institute of Health (NIH) for a study of non-syndromic POI²⁹. These subjects were re-consented to have their DNA undergo WES at Washington University (LMN, ARC and ERM). A third cohort was recruited from Pittsburgh (n=20), Italy (n=43) and France (n=32)(AR and PT). All Boston subjects underwent a medical history and physical exam and family history. Subjects from the NIH, Pittsburgh, Italy and France had limited phenotypic data.

Control subjects for category-wide association using GEM²⁴ included 96 unrelated, unaffected subjects recruited for health in old age and 137 CEU, FIN and GBR samples from the 1000 Genomes Project (total n=233 controls)^{30,31}. The majority of CEU samples are from Utah families recruited for large family size (n=47 of 61)³². The control subjects underwent whole genome sequencing, as previously described³³. All subjects provided written, informed consent from the University of Utah, Washington University, University of Pittsburgh or the Sorbonne Universite IRB.

Methods

DNA samples were extracted (Qiagen) and subjected to WES. The Boston cohort was sequenced using the Illumina HiSeq 2000 (Illumina). All candidate susceptibility variants in the Boston cohort were Sanger sequenced for verification. Sequencing of the NIH/Washington University cohort was performed using the Roche NimbleGen VCRome 2.1 (HGSC design) exome capture and the Illumina HiSeq 2500 for sequencing at the McDonnell Genome Institute at Washington University. The dataset was accessed through dbGAP (NIH approved request #47895-1, Project #11971). The Pittsburgh, French and Italian cohorts were sequenced at the

Pittsburgh Clinical Genomics Laboratory using the Haloplex Exome Target Enrichment System or the Agilent SureSelect V5 Capture Kit (Agilent Technologies, Santa Clara, CA), and 2x 100 bp paired-end WES was performed on an Illumina HiSeq 2500 (San Diego, CA, USA).

The control subjects' DNA underwent whole genome sequencing (WGS) using the Illumina X Ten sequencing platform (Nantomics, Culver City, CA). The comparison of variants in cases using WES versus controls using WGS would result in a conservative estimate of variants in cases based on the higher coverage expected from WGS.

Alignment and Variant Calling

Alignment and variant calling were performed by the Utah Center for Genetic Discovery (UCGD) core services. Fastq files were downloaded from the Pittsburgh Clinical Genomics

Laboratory and dbGAP. Variants were called through the UCGD pipeline using the Sentieon software package (https://www.sentieon.com) ³⁴. Reads were aligned to the human reference build GRCh37 using BWA-MEM (Burrows-Wheeler Aligner). SAMBLASTER was used to mark duplicate reads and de-duplicate aligned BAM files. Aligned BAM files underwent INDEL realignment and base recalibration using Realigner and QualCal algorithms from the Sentieon software package3 to produce polished BAM files. Each polished BAM file was processed using the Sentieon's Haplotyper algorithm to produce gVCF files³⁵. Sample gVCF files were combined and jointly genotyped with 728 samples comprised of the 1000 genomes project (CEU) samples and samples unrelated to reproduction or cancer phenotypes to produce a multi-sample VCF file. To produce the final VCF variant quality scores, VCF files were recalibrated using Sentieon's VarCal algorithm to estimate the accuracy of variant calls and reduce potential false positive calls.

Quality Control

Quality control algorithms were applied to sequence reads (Fastq files), aligned reads (BAM files) and variants (VCF files)³⁶. Fastp was used to evaluate read quality, read duplication rate, presence of adapter and overrepresented sequences in Fastq files³⁷. Indexcov was used to estimate depth and coverage of aligned sequence data using BAM indexes. Further alignment quality metrics were calculated on BAM files with samtools stats. The 291 cases were sequenced using different exome capture kits, we therefore standardized QC analysis regions with a bed file made up of exonic regions from coding gene models from RefSeq and Ensemble gene sets. These regions were used to obtain the total number of reads, percentage aligned reads and mean and median coverage for all samples.

Variant quality metrics were calculated by running bcftools stats³⁸⁻⁴⁰. The overall quality of VCF callsets were evaluated using Peddy to confirm sex, relatedness, heterozygosity and ancestry of each individual and identifying potential sample-level data quality issues⁴¹.

Identification of Damaging Gene Variants

For each case, the uploaded VCF file was scored with VAAST Variant Prioritizer (VVP) and Variant Annotation Analysis and Search Tool (VAAST) to prioritize potentially deleterious variants and damaged genes^{25,42}. VVP and VAAST use a likelihood ratio test (LRT) to score each variant and the aggregate burden of variants for each gene in affected individuals relative to a set of 2,492 control genomes of healthy individuals from the 1000 Genomes Project⁴³. The LRT incorporates three components of each variant; the severity of amino acid substitution, phylogenetic conservation of the variant, and the frequency of the variant relative to the control population. The sum of the top scoring variant(s) based (one variant for dominant inheritance and two variants for recessive inheritance) represents the cumulative likelihood ratio (CLR) for a given gene. The significance of each gene's VAAST CLRT score is evaluated by a permutation test that randomizes the case/control status of individuals in each of 1e⁶ permutations and

generates a permutation *p* value for the gene. The output from VAAST is an ordered gene list ranked for the probability of being damaged relative to the control genomes.

Variants identified in the VAAST analysis above were further refined by selecting only variants found at a minor allele frequency (MAF) <0.001 and with no homozygotes found in gnomAD^{44,45}. The choice of a MAF <0.001 cutoff was based on the frequency of the fragile X premutation. The prevalence of the premutation in the population is 0.004 and it is the most common single gene cause of POI identified to date. A fragile X premutation accounts for only 6% of sporadic POI cases⁴⁶, making 0.001 a conservative upper bound for the risk attributable to any one gene. We also removed variants in genes known to tolerate a large burden of genetic variation such as olfactory receptors, snoRNAs, mucins and T cell receptors⁴⁷. Finally, we required an Omicia score of >0.7; a meta-classifier that combines scores from SIFT, PolyPhen, MutationTaster and PhyloP to predict pathogenicity⁴⁸⁻⁵³. A range of 4-25 damaging gene variants were found per person.

GEM Analysis

We also used GEM to identify gene variants in each subject that were most likely to be pathogenic²⁴. GEM is an Electronic Clinical Decision Support System (eCDSS) framework that aggregates and adjudicates data from multiple algorithms and clinical datasets to provide rapid and accurate diagnosis of individual genomes²⁴. GEM generates a Bayes Factor-based score that calculates the degree of support for and against a given model (a gene allele is pathogenic vs. benign) considering multiple lines of evidence from the following variant analysis tools and data sources: VVP, VAAST, Phevor, mode of inheritance for disease genes from Online Mendelian Inheritance in Man (OMIM), pathogenicity of variants (ClinVar), population specific allele frequencies (gnomAD), quality of variants and the overall genome (data) and quality of the genomic location (gnomAD)^{25,26,42,44,54-56}. Using this data, GEM identifies potentially pathogenic genotypes and evaluates support for their association with disease. Gene variants for each

subject were considered candidates if they had a GEM score \geq 1 (strong support for the model of pathogenicity)⁵⁷, together with genes having a GEM score \geq 0.69 (substantial support for the model of pathogenicity), and a Phevor Bayes factor \geq 0.9 (genes with a strong association with POI)⁵⁴. One to twenty-four gene variants were identified for each subject.

Creating Categories for Enrichment Analysis

We used the Database for Annotation, Visualization and Integrated Discovery (DAVID) to functionally annotate known POI genes and candidate genes identified in model organisms ^{14,58}. The analysis yielded 47 clusters with one removed for too few genes (<20; Cluster 37)(Supplementary Table 1). Cluster 37 contained mismatch repair genes, but the genes were also found in other clusters and was therefore redundant.

Calculating Gene Burden on Resampled Gene Lists and Housekeeping Genes

We randomly selected 146 genes from a list of housekeeping genes that are constitutively expressed over many developmental time points in 16 tissue types (Supplementary Table 2). We ensured that none of the housekeeping genes were found in our gene sets identified in the GEM analysis. In addition, we created a burden-matched set of genes. For this, we created a burden ratio for every gene by summing the number of rare variants (MAF ≤ 0.005)⁵⁹ in the longest coding transcript of each gene and dividing by transcript length. For each decile in the distribution of this burden ratio, we determined the mean and standard deviation of the burden ratio. We then used these mean and standard deviations to generate randomly sampled gene sets for each decile that had matched mean and standard deviation for burden ratio. These burden matched gene sets were used to test the significance of gene set enrichment in the subjects.

Permutation Tests and Case/Control Comparison

For the permutation tests and analysis, we used the GEM results with a GEM score ≥ 1 generated from the POI cases and control individuals to test for enrichment in individuals with POI compared to controls. Both sets of data generated GEM results using two different HPO terms: POI (HP:0008209) and phenotypic abnormality (HP:0000118) to create 4 sets of data: Cases POI, Cases Phenotypic Abnormality (root), Controls POI, Controls Phenotypic Abnormality (root). The reason we ran GEM using the root of the HPO ontology (Phenotypic Abnormality) was to control for overly connected genes that might have inflated Phevor scores, thus reducing biases due to the nature of the ontology. We then determined the number of damaged genes found in GEM results (number of successes) from genes listed in the individual pathways, a burden-matched gene list and a housekeeping gene list.

Permutation analyses were performed using a random sampling strategy to evaluate enrichment of the POI dataset against gene lists related to functional aspects of the disease. A gene list containing 18,876 RefSeg genes was first created, excluding mucins and olfactory receptor genes. For each functional gene list of size N, random samples of equal size were drawn from the 18,876 genes. This process was repeated 100,000 times, each time with an independently generated random gene list, to create an empirical distribution of the number of damaged genes (GEM score ≥ 1) for each functional gene list. To test whether the probands show enrichment in the functional gene lists, the actual number of damaged genes found for each list was compared to the distribution of damaged genes found using burden-matched gene lists and the housekeeping genes list. To test for statistical significance, we used Fisher's exact test to calculate a p value using the 2x2 contingency table testing the hypothesis that the number of damaging genes that matched the functional list was significantly larger in the POI GEM runs than in the root Phenotypic Abnormality GEM runs. All p values were adjusted for multiple testing (False Discovery Rate, FDR). To generate a final score depicting the most significantly enriched pathways, adjusted POI p values were divided by Phenotypic Abnormality p values to generate a normalized score that represents enrichment. The higher the ratio, the

more enriched the pathway. Pathways with a corrected p value <0.05 and a \log_2 ratio of greater than 2 for the POI p value/Phenotypic Abnormality p value were considered significant pathways.

Oocyte Expression

To determine whether candidate genes are expressed in mammalian oocytes, 35 dayold female mice were treated with an intraperitoneal injection of 5 IU PMSG to initiate follicular
development and 5 IU hCG 48 hours later to induce ovulation⁶⁰. Eighteen hours later, mice were
sacrificed, oviducts dissected to remove oocytes and cumulus cells manually removed. RNA
was isolated from oocytes using RNeasy (Qiagen, Valencia, CA)⁹. Reverse transcription was
performed with SuperScript Master Mix (Life Technologies, Carlsbad, CA) using SuperScript III
RT and random primers. Quantitative real-time polymerase chain reaction was performed for
the expression of candidate genes and glyceraldehyde-3-phosphate dehydrogenase (*Gapdh*) as
an endogenous control using PowerUp SYBR Green Master Mix (Applied Biosystems, Foster
City, CA). Primers were designed to span two exons to avoid amplifying genomic DNA. Primer
sequences are provided (Supplementary Table 3). Samples were examined in triplicate and at
three dilutions. mRNA levels were determined using the 2^{-ΔΔCT} method to calculate relative
quantification and to correct for expression of endogenous controls.

Functional Analysis

Flies were raised at 25° C on standard diet based on the Bloomington *Drosophila* Stock Center standard medium with malt. We obtained 20 RNAi lines from the Bloomington *Drosophila* Stock Center. Ovary/germline specific RNAi knockdowns were performed using Gal4 DNA-binding protein and Upstream Activator Sequence (*GAL4/UAS*) technology, as previously described⁶¹. We crossed flies carrying the *Maternal Triple Driver-GAL4* (*MTD-GAL4*; BDSC 31777) transgene to flies carrying each respective UAS-RNAi transgene to generate female flies

with ovary specific knockdown of each gene. Control flies were generated by crossing flies carrying the MTD-GAL4 transgene to the appropriate AttP RNAi background strain (does not carry UAS-RNAi transgene). Virgin female RNAi knockdown (and control) flies were collected on CO₂ anesthesia and aged 3-5 days on standard media supplemented with dry yeast. Female knockdown flies were singly mated with a 3-5 day old Canton S male. Individual mating pairs were observed to ensure successful mating. Males were removed after mating. We measured four female reproductive phenotypes: 1) egg number: number of eggs laid in first 8 hrs post mating; 2) hatchability: number of adults that hatched from those eggs; 3) total fertility over 10 days post mating; 4) overall ovary appearance and morphology⁶². For egg number, newly mated females were place in vials for 8 hrs and egg number was counted. For hatchability, all the progeny that eclosed from the egg number vial were counted (progeny #/egg #). To measure total fertility, mated females were transferred to new vials every two days for ten days and all the progeny were summed over the entire period. For ovary images, adult females were collected under CO₂ anesthesia, dissected and immediately imaged. Ovaries were imaged at 3X magnification using a Leica EC3 camera. We assayed at 8-10 females per RNAi knockdown. Statistical analysis was performed using R software. P-values were determined using ANOVA. A p value < 0.05 was used for significance.

Results

Whole exome sequencing produced a mean of 96 million reads per individual (range 31-186 million) and an average of 99.6% mapped/aligned reads to the GRCh37 human reference genome with an average duplication rate of 8.4% (Supplementary Figure 1A-C) for the 280 samples that passed QC metric cutoffs. Fastp identified read quality and insert sizes within the normal ranges. Variant calling produced an average of 21,923 SNVs and 576 indels per sample, with an average depth of 55x per sample (Supplementary Figure 1G-I). Peddy was used to infer the sex, heterozygosity, ancestry, and relatedness of subjects, and compared to known metadata about samples (Supplementary Figure 2A-D)⁴¹. From these quality control metrics we identified and removed four samples (Supplementary Table 4) that had very low heterozygosity and low coverage. Three samples were removed due to high duplication rates. One sample was removed due to excess heterozygosity. We also discovered a previously unidentified deletion of the long arm of the X chromosome (93.7% homozygous X:130678467-X:155171537) in sample IPOF32. In total, we removed 9 samples from analysis for the quality issues described above leaving 282 samples for the analysis. Peddy confirmed the sex of the POI subjects (Supplementary Figure 2A), and the known relatedness of a few individuals (Supplementary Table 5, Supplementary Figure 2D-E). An additional four sib pairs were identified in the cohort and one family with dominant inheritance was included (Supplementary Figure 2E). For these related individuals, only one subject was included in the joint analyses. PCA projection of the samples together with data from the 1000 genomes identified individuals of European descent (n=235), admixed American (n=18), African (n=10), South Asian (n=4), East Asian (n=3), and unknown (n=12) ancestry (Supplementary Table 6, Supplementary Figure 2C).

In 19 subjects, we identified variants in genes previously determined to cause POI, including confirmation of previously identified variants in 12 subjects with primary amenorrhea (6.7%; Table 1)^{19,63-66}. Five of these variants were found as heterozygous genotypes in the genes *NR5A1*, *PTPN22* and *eIF4ENIF1*^{9,17,67}.

Sixty-four subjects (23%) carried at least one variant in a previously identified POI gene that was determined to cause ovarian dysgenesis or primary amenorrhea with autosomal recessive inheritance (Table 2). Twenty-seven subjects (10%) carried a heterozygous variant in a gene for which there was a previously identified functional model (Table 3)^{68,69}. Variants at genomic loci that were not conserved across species were not considered for analysis, although variants impacting conserved amino acids that were found only in mammalian species were included. One subject carried two variants in *FANCM* and one subject carried two variants in *RECQL4*, however, it was not possible to confirm whether these variants were in *cis* or *trans*. Fourteen subjects carried 2, one subject carried 3 and one subject carried 4 candidate POI risk variants in different genes.

We next determined gene clusters for known genes for POI in women and candidates from animal models. DAVID analysis identified 47 gene list clusters with enrichment >2 (Supplementary Table 1). We then examined enrichment of these 47 gene sets in women with POI compared to controls and found 13 significant gene sets. These gene sets encompassed GO term biological processes including transcription/translation, DNA damage and repair, oogenesis, cell proliferation, hormone regulation, growth factors, regulation of gene expression, embryogenesis, cytoplasmic signaling, male gonad development, chromatin binding, cell division and protein phosphorylation (Table 4, Figure 1). Further, there was significant enhancement compared to housekeeping genes and burden-matched gene lists in POI cases compared to controls (Figure 1A-C and Supplementary Table 2). The majority of the causal or candidate genes were found in the enriched gene sets (Tables 1-3). The two genes that were not found in the gene lists are important for meiosis (*MARF1* and *ANKRD31*).

We examined the remaining candidate genes that had not yet been implicated in a woman with POI or in an animal model. We identified several deleterious variants in genes found in the implicated gene sets (Table 5)⁷⁰⁻⁷⁷. None of these gene variants was identified in the control groups that we assessed. Additional candidates were identified in these and other

gene sets, although their pathogenicity was not as strong based on conservation, allele frequency or gene constraint (Supplementary Table 7).

Functional Studies

The potential pathogenicity of the variants not previously identified is outlined in the Supplementary Data (Supplementary Information). For genes with variants not previously identified in POI or in animal models of POI or not previously examined in oocytes (Table 5), RTPCR in mouse oocytes that have resumed and/or completed meiosis I was performed to ensure that the candidate gene was expressed. Of the 24 genes tested, four were present but not highly expressed in the oocyte (Table 5 and Supplementary Tables 3 and 8).

D. melanogaster orthologues were identified for 20 of 35 candidate genes queried (Supplemental Table 9). Thirteen candidates could not be obtained based on availability or could not be tested based on lack of orthology or absence of ovarian expression. Two of the candidates had multiple weak orthologues and were not pursued (*POLK* and *ANKRD31*).

Five knockdowns (*USP36, VCP, WDR33, PIWIL3* and *NPM2*) were completely infertile with atrophic ovaries (Table 6 and Supplementary Figures 18 and 19). Two gene knockdowns demonstrated decreased hatchability and fertility, with abnormal (*LLGL1*) or normal ovaries (*BOD1L1*). Two gene knockdowns had variable or mild ovarian defects that were not statistically significant (*CDK7* and *BRIP1*). One gene knockdown was lethal (*RUVBL2*).

Discussion

We performed WES in 291 subjects with POI from three cohorts. Using two methods, a broad and unbiased discovery method and a more robust prioritization algorithm (GEM), we identified the most likely pathogenic variants in these women with POI. Our data suggest that the candidate genes for POI in individual women are highly heterogeneous. However, when the most likely candidate genes were categorized into functionally related groups, the genes aligned into 13 clusters that were enriched in cases compared to controls after correcting for multiple testing, gene size and pathogenic specificity for POI. New candidate genes were found in enhanced gene sets that included genes important for transcription/translation, DNA damage and repair, meiosis and cell division. Functional analysis in *D. melanogaster* supported a role in oocyte or ovary development for seven genes not previously associated with POI. Taken together, the data support a categorical approach to understanding the genetic architecture for POI.

After an initial broad search for damaging variants, we used an AI-based eCDSS tool, GEM, that employs variant impact (VAAST and VVP), patient phenotypes (Phevor), known Mendelian and pathogenic variants (OMIM, ClinVar) and ancestry to identify disease-causing genotypes ^{15,24,25,42,54}. Using GEM, we supplemented our data with previously analyzed WESs and have replicated genetic findings in 11 out of 12 subjects with primary amenorrhea, demonstrating the utility of the new software. The only gene variant that was not identified was in *MARF1*, which has not yet been associated with POI in OMIM. GEM identified additional homozygous or compound heterozygous mutations (*HFM1*, *DCAF17*) or heterozygous mutations (*NR5A1*) in previously identified genes⁷⁸⁻⁸⁰.

GEM also identified heterozygous deleterious variants in known genes, particularly in women with POI and secondary amenorrhea. GEM uncovered variants in 28 genes previously demonstrated to cause POI with recessive inheritance, out of 42 gene variants total (67%).

GEM also identified 13 of 20 candidate variants in genes with evidence for ovarian insufficiency

in an animal or other experimental species model (65%). The results are not surprising based on the use of HPO POI terms in the algorithm, which emphasizes phenotype in GEM⁵⁴. Further tool development will encompass gene pathways for discovery.

With the exception of subjects with POI and primary amenorrhea, the majority of candidate variants identified in the current study are heterozygous, arguing for a dominant, semi-dominant, or complex inheritance pattern for POI that occurs later in the reproductive years. Genome-wide association studies (GWASs) of age at natural menopause support the concept that menopause has a complex inheritance pattern⁶⁸. Further, the largest GWAS of early menopause, defined as menopause before the age of 45 years, replicated 4 common variants associated with age at natural menopause and demonstrated that menopause risk alleles have an additive contribution to age at menopause²¹. Recent data also suggest that common variants contribute to menopause occurring as early as 34 years²². However, the contribution of common variation explains only a small portion of the genetic risk for menopause under age 40 years²². The current study using WES was not able to assess common variants, but did demonstrate overlap between common GWA variants and rare, deleterious variants in the same candidate genes. For example, nonsynonymous variants in BRCA1 are associated with earlier menopause by approximately 6 months⁶⁸. In the current study, we identified a frameshift mutation, expected to result in early protein termination, possibly causative for POI. Additional genes with deleterious variants (MSH6, CHD7) and some with rare missense variants (RAD54L, HELQ, POLG) also overlap with candidate genes associated with age at natural menopause (Table 2). The apparent overlap of common variants associated with menopause age and deleterious variants in the same candidate genes is consistent with the hypothesis that mutations in these genes play a causative role in POI.

Further support for the causative role of heterozygous gene variants in POI comes from the reproductive history of the mothers of girls with primary amenorrhea. A heterozygous *MND1* gene mutation in a mother resulted in POI at age 35 years⁴⁵. Similarly, a heterozygous mutation

in *MCM8* caused POI in a mother at age 29 years¹⁸. In both families, the daughters with homozygous mutations presented with primary amenorrhea. With the exception of a few reports, age at menopause is rarely mentioned or may not yet have occurred for mothers of girls with POI. However, age at menopause is heritable supporting the segregation of ovarian damaging genes with an effect on age at menopause through the mother³. It is also not surprising that heterozygous variants that relatively decrease fertility would be removed from the population through decreased progeny⁸¹, and might therefore be inherited from the father since reproductive lifespan is not limited in men. Taken together, these cases also support the hypothesis that heterozygous mutations can result in earlier age at menopause.

Although the number of subjects in the current study is not sufficient to replicate the genes individually, we were able to demonstrate significantly enriched gene clusters controlled for multiple testing. Previous work in autism and congenital heart disease has used a similar category-wide association study approach^{27,28}. Our approach was unbiased; first examining the most deleterious variants in women with POI to identify known genes and candidates with previous functional models, and subsequently determining whether additional genes were found in the clustered gene sets. Interestingly, a MAGENTA analysis of age at natural menopause variants identified similar enhanced categories for candidate genes inferred from genome-wide associated variants⁶⁸. In addition, known genes causing male azoospermia were enriched in comparable pathways⁸². Taken together, a category enhanced approach identifies consistent gene sets across reproductive studies. Genes falling into gene sets including oogenesis, spermatogenesis, meiosis, DNA damage and repair, transcription and translation, chromatin binding, regulation of gene expression, growth factors, embryo development, cell division, extracellular to cytoplasmic signaling, protein kinase phophorylation, and vasoactivity and hormone regulation were enriched compared to controls in our unbiased candidate gene search for damaging mutations across the genome (Figure 1)83. New candidate genes were identified

within these gene sets demonstrating that the category approach provides a mechanism for new candidate gene discovery.

Our *D. melanogaster* knockdown model affords a mechanism to determine an oocyte and ovarian phenotype at scale for genes in enhanced pathways. The genes and developmental processes involved in oogenesis in *D. melanogaster* overlap with those in the mouse⁸⁴. We chose quantifiable fertility assays including egg laying rates, hatchability and ovarian morphology⁶². The use of RNAi technology also presumes that the gene is not fully deleted and serves as an excellent model for heterozygous gene variants. Using our *D. melanogaster* model, we identified five genes that are critical for ovarian or oocyte development and that fall into the enriched pathways we defined: transcription/translation, meiosis, DNA repair and DNA damage. RNAi knockdown resulted in atrophic ovaries with no eggs or progeny (Table 6 and Supplementary Figures 18 and 19).

USP36 is a deubiquitinase demonstrated to promote RNA polymerase I stability for the ribosomal RNA processing and translation⁸⁵. Previous studies found that the scny *D. melanogaster* homologue also acts as a histone H2B ubiquitin protease⁸⁶. The atrophic ovary in the knockdown shows that the ribosomal RNA translation and/or the chromatin modification function may affect oocyte or ovarian development in addition to its role in embryogenesis⁸⁵.

WDR33 plays a role as one of 4 proteins that recognize the polyadenylation signal in the 3'-end processing of mRNA precursors⁸⁷. The gene is highly expressed in testes and we have now demonstrated that it is also highly expressed in mouse oocytes (Supplementary Table 8). RNAi knockdown results in an atrophic ovary. Thus, WDR33 may also play critical role in ovarian or oocyte development.

PIWIL3 is a P-element induced wimpy testis protein short RNA found in human, nonhuman primate and bovine oocytes. It is specifically expressed in maturing human oocytes during oogenesis⁸⁸ and in bovine oocytes from the GV stage onward⁸⁹. It is critical for germline integrity from DNA transposable element activity⁹⁰. The affected subject carries two *PIWIL3*

variants; a frameshift mutation and a stop gain mutation that both remove the PIWI domain from the protein⁹⁰. We also identified a stop gain mutation in *PIWIL2*, a family member that is expressed in fetal human germ cells⁸⁹. Although knockouts of the mouse *PIWIL2* homologue *Mili* were described as fertile, there were no details provided across the reproductive lifespan⁹¹. These data demonstrate the importance of the *PIWIL* genes in the ovary in addition to the testes.

NPM2 is found in oocytes before germinal vesicle breakdown⁹². The *Npm2* knockout females are infertile, with normal sized pronuclei that lack nucleoli^{92,93}. Although previous studies suggest that infertility is caused by failure of zygote development, our data suggest that *NPM2* is critical for oocyte and ovary development.

VCP, or valosin-containing protein, is an ATPase associated with a variety of activities⁹⁴. It is expressed in GV oocytes and preimplantation embryos in the mouse and controls germinal vesicle breakdown. *Vcp* knockout mice demonstrate no homozygotes because they have a defect in early embryonic development. Our model demonstrates atrophic ovaries. A missense variant in a highly conserved threonine in the N terminal was found in two sisters and a mother with POI (Supplementary Figure 2E). The N terminal is the portion that interacts with other proteins. Therefore, VCP should be considered a new candidate for POI.

In contrast to genes described above, there were only subtle phenotypes identified using our model in genes associated with DNA damage and repair pathways. Two genes in the pathway, *LLGL1* and *BOD1L1*, were highly expressed in the oocyte and demonstrated decreased hatchability and decreased fertility. The *LLGL1* cytoskeletal network is involved in maintaining cell polarity and epithelial integrity⁹⁵. Mutations including the gene region on chr 17 cause Smith Magenis syndrome, a disorder of developmental delay, behavioral abnormalities, sleep disturbance and abdominal obesity. An indel upstream of *LLGL1* in Shaanbei White Cashmere goats is associated with change in litter size⁹⁶. *BOD1L1* stabilizes *RAD51* at the site of DNA replication forks⁹⁷. The frameshift variant in our subject would remove all ATM

phosphorylation sites, along with the majority of the protein. Other genes in the DNA damage and repair pathway with no previous functional models or human mutations had no phenotype in our *D. melanogaster* model and more sensitive functional models may be needed.

Nevertheless, a number of previously well validated variants involved in the homologous recombination steps in meiosis were discovered in our cohort (Figure 2)⁸³. Many of these gene mutations may result in meiotic failure and oocyte loss. Given the large number of gene mutations falling into the DNA damage and repair pathway, intervening to rescue meiosis for development of normal gametes may be a treatment opportunity in POI.

An association between autoimmune oophoritis, with POI as the end-stage, has been demonstrated only with adrenal autoimmunity⁹⁸. We identified a novel *PTPN22* variant, a gene associated with adrenal insufficiency, and in *TARBP1*, a gene associated with autoimmune syndromes^{99,100}. A final subject carried a variant in IL1B, which has been associated with ovarian inflammation. Further delineation of the associated autoimmune risk genes and diseases will clarify the relationship between autoimmunity, genetics and POI.

Our study is limited by whole exome sequencing. We were not able to evaluate common variation, some promoter regions and could not evaluate copy number variants. We did not have trios for the majority of subjects and did not recruit family members to clarify segregation or *de novo* mutations. Future studies will also be needed to more carefully analyze the mitochondrial genome.

The current cohort forms one of the largest WES datasets analyzed for POI. We used an unbiased approach and a new Al-based algorithm to identify the most likely pathogenic variants. We also demonstrated new genes important for oogenesis and ovarian development using a model *D. melanogaster* system. Our more global approach contrasts to previous studies that examined individual consanguineous families and/or were restricted to candidate gene lists. Collectively, our results identify not only disease-causing variants, but also gene categories involved in POI. These results should prove useful for precision medicine efforts aimed at early

identification of gene variants increasing a woman's likelihood to experience infertility or a shortened reproductive lifespan. The early identification of women at risk for POI may enable fertility preserving measures. More broadly, better understanding of the genetic architecture of POI might also aid in identifying additional comorbid risks in a subset of the subjects.

Acknowledgements

The work in this publication was supported by the Center for Genomic Medicine and its Functional Analysis Service. The work was also supported by R56HD090159 and R01HD099487 (CKW) and R35GM124780 (CYC and EC). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Table 1. Candidate variants in previously identified genes causing POI.

Gen e	Chr: Locati on	Codi ng Chan ge	Protein Change	Zyg osit y	Cons eque nce	gnom AD Allele Frequ ency (Fem ale/M ale)	Cons ervati on ¹	POI ID	Pri mar y-1 or Seco ndar y-2 (Age yrs)	Refe renc e ²	z sco re or Ob s/ex p ³	Gene Set ⁴
HF M1	1:9181 6375	c.212 3A> T	p.Ile709 Asn	Ho mo ⁵	Misse nse	Novel	M(not C)XZ L	NIH 897	31 5)	78	0.7	16,40
PTP N22	1: 11438 0534	c.148 8A> C	p.Glu49 6Asp	Het	Misse nse	0.000 072 / NA ⁶	M	118 96X 16	2 (34)	67	0.8 7	7,9,11, 32,40
FSH R	2:4919 0159	c.180 1G> C	p.Leu60 1Val	Co mpo und Het	Misse nse	Novel	MCX ZL	FP OF2 8	1 (19)	65 2	-0.8	1,5,7,1 1,25,32 ,40
	2:4919 0405	c.155 5G> T	p.Pro51 9Thr	Ho mo	Misse nse	Novel	MCX ZL	FP OF2 1	1 (17)	64 2	-0.8	
	2: 49190 686	c.127 4C>T	p.Thr42 5Ile	Co mpo und Het	Misse nse	Novel	MCX Z(not L)	FP OF1 2	1 (18)	63 2	0.8	
	2:4919 0751	c.133 4>T	p.Asn40 3Tyr	Co mpo und Het	Misse nse	Novel	MCX (not Z)L	FP OF1 2	1 (18)	63 2	0.8	
	2:4919 6020	c.671 T>A	p.Asp22 4Val	Co mpo und Het	Misse nse	NA / 0.000 05721	MCX ZL	FP OF2 8	1 (19)	65 2	0.8	
DCA F17	2:1723 06465	c.535 C>T	p.Gln17 9Ter	Co mpo und Het	Stop Gain	0.000 0719 / NA	NA	PP OF1 42	1	66 2	0.5 3 (0.3 5- 0.8 2)	7,16,25
	2:1723 25465	c.906 G>A	p.Trp30 2Ter	Co mpo und Het	Stop Gain	NA / 0.000 0147	NA	PP OF1 42	1	66 2	0.5 3 (0.3 5- 0.8 2	
GD F9	5:1321 97489	c.116 1C>	p.Cys38 6Phe	Ho mo	Misse nse	Novel	MCX Z	FP OF1	1 (17)	63 2	0.5	7,11,25 ,32,40

		A						0			7	
HAR	5:1400	c.101	p.Tyr33	Но	Misse	0.000	MCX	Fpo	1	63 2	0.0	7,16,40
S2	76804	0A>	7Cys	mo	nse	00866	ZL	F32	(27)		4	
1.00		G	m	~	3.51	/ NA	3.54			63,101	4.4	7 1 5 10
MC	6:	c.178	p.Thr59	Co	Misse	Novel	M(not	FP	1	2	1.4	7,16,40
M9	11914 7976	5G> C	5Ser	mpo und	nse		eleph ant or	OF3 8	(20)		3	
	1910			Het			Z)CX	0				
	6:	c.164	p.Gln55	Но	Stop-	0.000	NA	FP	1	63,101	0.6	
	11914	9A>	1Ter	mo	gain	017 /		OF2	(20)	2	4	
	9171	C				0.000		4	, ,		(0.4	
						0148					7-	
											0.8	
	6.1102	2.005	NIA	Co	Colin	0.000	MCV	ED	1	63,101	7)	
	6:1192 34586	c.905	NA	Co	Splic e	0.000 0088 /	MCX ZL	FP OF3	(20)	2	4	
	34360	1G>		mpo und	Acce	0.000	ZL	8	(20)		(0.4	
		T		Het	ptor	0075					7-	
					P						0.8	
											7)	
NR5	chr9:	c.109	p.Arg36	Het	Misse	Novel	MCX	FP	1	63,102	2.3	5,7,13,
A1	12725	5G>	5Trp		nse		(not	OF	(14)	2	4	25
	3405	A 100	C126	TT.4	C4	N 1	ZL)	8			0.0	
	chr9: 12725	c.108 4C>T	p.Gln36 2Ter	Het	Stop Gain	Novel	NA	IPO F17			0.0 06	
	3414	40/1	2101		Gaili			1.17			(0.0)	
	3414										2-	
											0.2	
											6)	
	9:1272	c.253	p.Arg84	Het	Misse	Novel	MCX	NIH		79	2.3	
	62988	C>A	Leu		nse		ZL	930		63 2	4	
PM	16:889	c.255	NA	Co	Splic	0.000	MXL	FP	1	03.2		7,40
M2	8701	+1G>		mpo	e Dana	00866		OF1	(15)			
		A		und Het	Dono r	0.000		6				
				1101	1	0.000						
	16:890	c.323	p.Ala10	Co	Misse	0.000	MCX	NIH		103	_	
	0240	C>T	8Val	mpo	nse	00866	(not	811			1.3	
				und		/	ŽL)				9	
				Het		0.000						
	1.0000	25.5	T	~	3.5	0147	3.50==	\ -		103		
	16:890	c.338	p.Pro11	Co	Misse	0.000	MCX	NIH		103	1.2	
	0255	C>T	3Leu	mpo und	nse	0173 / 0.000	ZL	811			1.3	
				Het		0.000					2	
	16:890	c.484	p.Arg16	Co	Misse	0.000	MCL	FP	1	63 2		
	5531	C>T	2Trp	mpo	nse	00866	(not	OF1	(15)			
			r	und		/	XZ)	6	/			
				Het		0.000						
						0221						

MA	16:	c.168	p.Arg56	Но	Misse	Novel	MCX	FP	1	63 2	2.7	NA
RF1	15719	8G>	3Cys	mo	nse			OF1	(15)		3	Meiosi
	495	A						1				S
PSM	17:407	c.490	p.Arg16	Co	Fram	0.000	NA	FP	1	63 2	0.6	7,16
C3I	25368	CCT	6AlafsT	mpo	eshift	0087 /		OF4	(28)		2	
P	-	>C	er5	und		0.000		1			(0.3	
	40725			Het		0074					7-	
	370										1.0	
											8)	
	17:407	c.431	p.Leu14	Co	Fram	0.000	NA	FP	1	63 2	0.6	
	25549	A>A	4AspfsT	mpo	eshift	0087 /		OF4	(28)		2	
	-	TC	er2	und		0.000		1			(0.3	
	40725			Het		0074					7-	
	549										1.0	
										101	8)	
EIF	22:318	c.256	p.Pro85	Но	Misse	0.000	MCX	NIH		104	1.9	7,16,25
4EN	36842	4G>	5Leu	mo	nse	47 /	(not	790			9	,34
IF1		Α				0.000	L)					
7						4						
7	chr22:	c.603	p.Ser20	Het	Misse	0.000	MCX	134	2		1.9	
	31859	T>G	1Arg		nse	070 /	Z	29X	(40)		9	
	102					0.000		45				
						098						

¹Conservation – M-mammals including rhesus, mouse, dog, elephant, C-chicken, X-Xenopus tropicalis, Z-zebrafish, L-lamprey. Exceptions are noted in parentheses.

²Previously published

³Z score for missense variants and observed/expected (90% confidence intervals) for loss of function variantsgnomAD.⁵⁹ A Z score >3 indicates a gene constrained for missense variants and an upper bound 90% confidence interval <1 indicates a gene constrained for loss of function variants.

⁴ DAVID Gene Sets: 1-oogenesis/spermatogenesis, 5-male gonad development, 7-transcription/translation/DNA binding, 9-regulation of gene expression, 11-growth factor/cytokine/TGFβ, 13-chromatin binding, 16-meiosis/DNA repair/homologous recombination, 25-extracellular to cytoplasmic signaling, 32-protein kinase/phophorylation, 34-cell division/meiosis, 40-cell proliferation/DNA damage. Also see Table 4. Other known biologic functions have been added for genes that were not found in DAVID.

⁵Homo = homozygous, Het = heterozygous

⁶NA = not applicable, i.e. not identified

⁷Confirmed by Sanger Sequencing

Table 2. Candidate variants found as heterozygotes in previously identified genes causing POI or associated with age at natural menopause.

Ge ne	Chr Loc atio n	Coding Change	Protein Change	Zyg	Con sequ ence	gnom AD Allele Frequ ency (Fem ale/M ale)	Conse rvatio n ¹	PO I ID	Pri ma r-1 or Sec ond ary -2 (Ag e yrs)	Ref ere nce 2	z sco re or Ob s/ex p ³	Gene Set ⁴
HF M1	1:91 8597 64	c.382T>C	p.Lys12 7Arg	Het ⁵	Miss ense	Novel	M	134 29 X5 5	2 (26)		0.7	16,40
<i>MS H6</i> ⁷	2: 4803 3757	c.3969_40 01+52dupT GAGA	NA	Het	Spli ce Site	Novel	NA ⁶	118 96 X6	2 (40)	105	0.3 4 (0.2 3- 0.5)	7,11,1 3,16,2 5,34,4 0
FS HR	2:49 1901 11	c.660delG	p.Pro61 6ProfsT er21	Het	Fra mes hift	Novel	NA	FP OF 30	1 (16)	63	0.8 3 (0.5 8- 1.2 2	1,5,7,1 1,25,3 2,40
FI GL A	2:71 0148 88	c.277G>T	p.Pro93 Thr	Het	Miss ense	0.000 31 / 0.000 37	MX	NI H6 07		106	0.0	1,7,11
	2:71 0177 70	c.1T>C	NA	Het	Start Lost	Novel	M	118 96 X9	2 (39)	106	0.6 3 (0.3 3- 1.3 2)	
IL1 B	2:11 3593 794	c.13G>T	p.Pro5T hr	Het	Miss ense	0.000 0463 / 0.000 0913	M	134 29 X5 3	2 (38)	107	1.1 5	7,9,11, 25,32, 40
LA RS 2	3: 4550 0250	c.622G>A	p.Asp20 8Asn	Het	Miss ense	Novel	MCX Z	134 29 X7 0	2 (23)	108	1.3	7,16,3 2,40
	3:	c.2675C>T	p.Pro89	Het	Miss	Novel	MCX	IP		108	1.3	

	4558		2Leu		ense		Z	OF			3	
MR PS 22	8985 3:13 9069 121	c.605G>A	p.Arg20 2His	Het	Miss ense	0.000 0232 / 0.000 0130	MCX Z	FP OF 34	1 (17)	109	0.1	7,25,4
	3: 1390 7163 5	c.878+2du pT	NA	Het	Spli ce Don or	0.000 00869 / NA	MCX ZL	NI H3 56		109	0.5 4 (0.3 4- 0.8 9)	
HE LQ	4:84 3487 61	c.2631A>T	p.Asp87 7Glu	Het	Miss ense	0.000 177 / 0.000 094	MCX ZL	NI H9 23		68,69, 110	0.6	7,16,4
	4: 8435 8150	c.1909C>T	p.Pro63 7Ser	Het	Miss ense	NA / 0.000 00738	MCX ZL	IP OF 11		110	0.6	
BM PR 1B	4:96 0368 40	c.341G>T	p.Thr11 4Ile	Het	Miss ense	0.000 0697 / 0.000 144	MCX Z	134 29 X1 7	2 (39)	20,11	7	7,11,1 6,32,4 0
	chr4: 9607 3907	c.1456C>T	p.Arg48 6Trp	Het	Miss ense	0.000 149 / 0.000 127	MCX ZL	NI H9 33		20,11	0.2	
	4:96 0757 86	c.1561C>G	p.Leu52 1Val	Het	Miss ense	0.000 00867 / 0.000 00738	MCX Z	NI H7 62		20,11	7	
MN D1	4: 1543 1548 3	c.349delA	p.Thr11 7Argfs Ter7	Het	Fra mes hift	Novel	NA	NI H8 99		45	0.8 9 (0.5 9- 1.4)	7,16
HS D1 7B 4	5: 1188 3775 8	c.1308dup A	p.Glu43 7Argfs Ter4	Het	Miss ense	Novel	NA	134 29 X4 3	2 (40)	16	0.5 3 (0.3 8 - 0.7	7,11,2 5,32,4 0
GD F9	5: 1321 9739 7	c.1251G> A	p.Pro41 7Ser	Het	Miss ense	Novel	MCX Z	134 29 X5 0	2 (21)	112	4) 0.7 (0.4 3- 1.1 9)	7,11,2 5,32,4 0
MC	6:	c.1477T>A	p.Lys49	Het	Stop	NA /	NA	PP		10	0.6	7,16,4

M9	1191 5026 2		3Ter			0.00 0012		OF 105			4 (0.4 7-	0
	2					42					0.8	
	6:11 9232 914	c.1051C>A	p.Val35 1Phe	Het	Miss ense	0.000 039 / 0.000 026	MCX ZL	NI H9 33		10	1.4	
	6:11 9234 571	c.919A>C	p.Leu30 7Val	Het	Miss ense	0.000 0174 / 0.000 0148	MCX Z	118 96 X4	2 (39)	10	1.4	
	6:11 9243 238	c.635G>C	p.Ser21 2Cys	Het	Miss ense	0.000 062 / 0.000 066	MCX Z	NI H9 26		10	1.4	
ST AG 3	7:99 7954 04	c.1069C>T	p.Arg35 7Ter	Het	Stop Gain	0.000 0087 / NA	NA	IP OF 36		8	0.4 5 (0.3 4- 0.6 1)	7,11,1 6,25,3 4,40
NO BO X	7:14 4098 166	c.815TC>T	p.Arg27 2fsTer1 4	Het	Fra mes hift	Novel	NA	PP OF 14		113	0.4 7 (0.3 - 0.7 6)	1,7,11
SPI DR	8: 4830 8973	c.563G>A	p.Ser18 8Asn	Het	Miss ense	0.000 368 / 0.000 367	М	134 29 X1 3	2 (37)	114	0.2	7,16
	8:48 5116 07	c.1393C>T	p.Leu46 5Phe	Het	Miss ense	0.00 0071 80 / NA	M	134 29 X2 9	2 (35)	114	0.2	
	8: 4862 5275	c.2029G> A	p.Asp67 7Asn	Het	Miss ense	0.000 258 / 0.000 262	MC	134 29 X4 0	2 (39)	114	0.2	
CH D7	8:61 7735 35	c.7681G>T	p.Gly25 61Ter	Het	Stop Gain	novel	NA	PP OF 105		68	0.0 4 (0.0 2- 0.0 8)	7,9,11, 13,16, 18,40
NB N	8: 9098 3470	c.633T>C	p.Asp21 1Glu	Het	Miss ense	0.000 0232 / 0.000	MCX	134 29 X7	2 (23)	115	0.6	7,11,1 6,34,4 0

						0392		0				
	8: 9098 3520	c.585- 2A>G	NA	Het	Spli ce	NA / 0.00 0007 402	MCX	NI H8 48		115	0.7 4 (0.5 6- 1.0 1)	
RE CQ L4	8:14 5737 353	c.3334C>T	p.Glu11 12Lys	Het	Miss ense	0.000 0179 / 0.000 0298	M	IP OF 28		116	4.2	7,16,2 5,40
	8: 1457 3852 2	c.2464- 1G>C	NA	Het	Spli ce Site	0.000 120 / 0.000 0922	MXZ L	134 29 X5 4	2 (40)	117	0.9 6 (0.7 7- 1.2 1)	
	8:14 5738 678	c.2386C>T	p.Glu79 6Lys	Het	Miss ense	0.000 0278 / 0.000 0261	MCX ZL	IP OF 28		116	4.2	
	8:14 5741 182	c.1223C>C A	p.Gln40 8fs12	Het	Fra mes hift	Novel	NA	NI H5 84			0.9 6 (0.7 7- 1.2 1)	
SE TX	9:13 5206 809	c.865C>T	p.Ala28 9Thr	Het	Miss ense	0.000 0433 / 0.000 00736	MCX Z	PP OF 21		118	0.1 1	1,7,13, 16,32, 34,40
SY CE 1	10:1 3536 9340	c.658_662 delGAGG G	p.Glu22 0ProfsT er5	Het	Fra mes hift	Novel	NA	NI H7 35		7	0.6 3 (0.4 2- 0.9 6)	1,7,34
	10:1 3537 0567	c.464+4	NA	Het	splic e	Novel	M	FP OF 30	1(1 6)	7	0.6 3 (0.4 2- 0.9 6)	
FA NC F	11: 2264 7025	c.332T>C	p.Leu11 1Pro	Het	Miss ense	0.000 0261 / 0.000 0294	MC	NI H8 30		119	1.8	1,7,16
	11: 2264	c.67G>T	p.Val23 Phe	Het	Miss ense	0.000 0390 /	MC	NI H4			1.8	

	7290					0.000		25			3	
						0196						
ZP	11:6	c.1364dup	p.His45	Het	Fra	0.000	NA	NI		120	0.9	11,25
1	0640	A	5GlnfsT		mes	02		H8			9	
	970		er93		hift			22			(0.7	
											501 .33)	
AT	11:1	c.216_217	p.Glu73	Het	Fra	NA /	NA	134	2	121	0.0	7,11,1
M	0809	CA	MetfsT	1101	mes	0.000	1111	29	(35)		6	6,32,3
	9934	G:	er26		hift	0131		X2			(0.5	4,40
		C						0			1-	
											0.7	
	11.1	- 1727T\ C	II. 576	IIa	Miss	Marial	MCV	NII		121	1)	
	11:1 0812	c.1727T>C	p.Ile576 Thr	Het	Miss ense	Novel	MCX	NI H7			1.1	
	2683		1111		clise			96				
	11:1	c.5882A>	p.Tyr19	Het	Miss	Novel	MCX	134	2	121	1.1	
	0818	G	61Cys		ense		Z	29	(40)			
	1006							X5		101		
	11:	c.7475T>G	p.Leu24	Het	Miss	Novel	MCX	NI		121	1.1	
	1082		92Arg		ense		ZL	H3				
	0110							56				
BR	13:3	c.1929delG	p.Arg64	Het	Fra	Novel	NA	FP	1	122	0.5	1,7,11,
CA	2910		5GlufsT		mes	_,,,,,,		OF	(16)		1	16,25,
2	420		er15		hift			17			(0.4	34,40
											2-	
											0.6	
7	13:3	c.5344C>T	p.Gln17	Het	Stop	Novel	NA	118	2	122	4) 0.5	
	2913	C.3344C/1	82Ter	Het	Gain	Novei	INA	96	(38)		1	
	836		02101		Cum			X3	(50)		(0.4	
								0			2-	
											0.6	
	10.0	05055 5	T 20	**	3.5	NT :	1.50**	**		122	4)	
	13:3	c.8585T>C	p.Leu28	Het	Miss	Novel	MCX	IP		1 22	1.2	
	2945 190		62Pro		ense		ZL	OF 14			1.2 9	
RE	14:2	c.126-	-2	Het	Spli	Novel	M	NI		123,1	0.4	1,7,16,
C8	4642	2A>G	splice		ce			H7		24	2	34,40
	106		•					27			(0.2	
											8-	
											0.6	
	14:2	c.388G>A	p.Glu13	Het	Miss	0.000	M	118	2	123,1	5)	
	4642	C.300U>A	0Lys	1161	ense	0.000	1 V1	96	(40)	24	7	
	546		J-1313		21150	0.000		X3	(10)		,	
						0369						
	14:2	c.884C>G	p.Pro29	Het	Miss	0.000	M	134	2	123,1	1.4	
	4647		4Arg		ense	723 /		29	(40)	24	7	

	316					0.000 617		X4 3				
	14:2 4647 872	c.1057A>C	p.Thr35 2Pro	Hom o	Miss ense	novel	M (exce pt elepha nt)	IP OF 2		124	1.4 7	
FA NC M	14:4 5605 596	c.362C>T	p.Ala12 1Val	Het	Miss ense	Novel	MCX ZL	IP OF 6		125	0.1 3	7,16,4
FA NC M	14:4 5633 715	c.1735C>T	p.Arg57 9Cys	Het	Miss ense	0.000 00771 / 0.000 0196	MCX L	IP OF 6		125	0.1	
FA NC M	14:4 5644 539	c.2583_25 86delTAA AA:T	p.Lys86 3IlefsTe r12	Het	Fra mes hift	0.000 0407 / 0.000 00849	NA	NI H8 75		125	0.4 6 (0.3 5- 0.5 9)	
SI X6 OS 1	14: 6095 0431	c.207_210 delTGAG	p.Ser69 ArgfsTe r53	Het	Fra mes hift	0.000 0181 / 0.000 0231	NA	118 96 X5	2 (19)	126,1 27	0.2 2 0.4 5 (0.3 - 0.6 9)	40
EIF 2B 27	chr1 4: 7547 1447	c.443_446 dupTGGA	p.Glu14 9Aspfs Ter16	Het	Fra mes hift	Novel	NA	134 29 X1 0	2 (39)	128	0.9 9 (0.6 6- 1.5 2)	7,16,3 4,40
PIF 1	15:6 5113 400	c.1051dup	p.Thr35 1Asnfs Ter52	Het	Fra mes hift	0.000 0542 / 0.000 0457	NA	IP OF 29		129	0.9 5 (0.6 9- 1.3 2)	7,16,4
PO LG	15:8 9865 023	c.2542C>T	p.Gly84 8Ser	Het	Miss ense	0.000 178 / 0.000 163	MCX ZL	IP OF 28		130	0.7 4	7,16,4
BL M	15:9 1312 735	c.2474C>T	p.Pro82 5Leu	Het	Miss ense	0.00 0017 3 / 0.00 0029	MCX ZL	NI H7 35		131	0.8	7,16,3 4,40

						43						
	15:9 1337 408	c.3031G> A	p.Gly10 11Arg	Het	Miss ense	0.000 00744 / 0.000 0175	MCX Z	PP OF 101		131	0.8	
	15:9 1347 405	c.3568dup A	p.Met11 90Asnfs Ter27	Het	Fra mes hift	Novel	NA	IP OF 3		131	0.5 6 (0.4 3- 0.7 5)	
NR 2F 2	15:9 6877 380	c.518A>G	p.Asn17 3Ser	Het	Miss ense	Novel	MCX	118 96 X1 7	2 ()	132	3.6	7,32,4
MA RF 1	16:1 5719 528	c.1654T>C	p.Ile552 Val	Het	Miss ense	0.00 0023 43 / 0.00 0104 7	MCX	118 96 X1 9	2 (19)	63	2.7	None, Meiosi s
	16: 1572 9800	c.544C>T	p.Glu18 2Lys	Het	Miss ense	NA / 0.00 0029 55	MCX	NI H 830		63	2.7	
PS MC 3IP	19: 1468 911 17: 4072 5043	c.5616dup C c.591- 1G>A	p.Ser18 73Leufs Ter280 NA	Het Het	Fra mes hift Spli ce Acc epto r	0.000 054 / 0.000 039	NA MCX ZL	IP OF 29 134 29 X3 9	2 (28)	133	0.6 2 (0.3 7- 1.0 8)	7,11,4 0 7,16
	17: 4072 9698	c.7T>C	p.Lys3 Glu	Het	Miss ense	0.000 00780 / 0.000 02614	M	NI H5 60		133	0.4	
BR CA 1	17:4 1209 079	c.5266dup T/TG	p.Gln17 77Profs Ter74	Het	Fra mes hift	0.000 2471 / 0.00 0123 9	NA	PP OF 39		68	Rec alc	7,9,11, 16,25, 34,40
AM H	chr1 9: 2249 397	c.67delG	p.Glu23 ArgfsTe r54	Het	Fra mes hift	Novel	NA	NI H 584		134	0.0 6	1,9,11, 25,32, 40,41

	19:2 2494 49	c.118C>T	p.Arg40 Ter	Het	Stop Gain	0.000 0166 / 0.000 0208	NA	NI H 881	134	1.2	
ZF				Het	Spli	0.000	MZ	118	112	0.9	11,16
R2					ce	306 /		96		7	
					Acc	0.000		X2		(0.7	
	19:3				epto	141		3		5-	
	8061	c.2644-			r					1.2	
	25	2A>G	NA						110	7)	
				Het	Fra		NA	IP	112	0.9	
					mes			OF		7	
					hift			38		(0.7	
	19:	c.755_768	p.Pro25							5-	
	3831	delCACCG	2GlnfsT							1.2	
3.77	384	CTTCC	er152	77 .	-	novel	27.4	DD	135	7)	7.0.11
NL	19:	c.2090_20	p.Lys69	Het	Fra	0.000	NA	PP	100	0.5	7,9,11,
RP	5653	91delAA	7Argfs		mes	195 /		OF		8	16,18,
5	9687		Ter18		hift	0.000 210		105		(0.4	32,40
						210				0.8)	
MC							MCX	NI		0.8)	7,16,2
M3							Z	H7		6	5,34,4
AP^8					Spli		L	77		(0.2	0
711	21:4				ce			, ,		7-	U
	7666				Don					0.4	
	541	c.4544C>T	NA	Het	or	Novel			136	9)	
	_						NA	IP		0.3	
								OF		6	
								19		(0.2	
	21:4	c.3810_38	p.Val12		Fra	NA /				7-	
	7676	12delA:AC	70Alafs		mes	0.000				0.4	
	826	G	Ter23	Het	hift	0572			136	9)	
AF	X:14		p.Tyr78	Hete	Miss	0.000	MCX	NI	137	1.4	7,16,4
F2	7743		Cys	rozy	ense	0309 /	ZL	Н6		1	0
	481	c.233A>G		gous		NA		22			

¹ Conservation – M-mammals including rhesus, mouse, dog, elephant, C-chicken, X-Xenopus tropicalis, Z-zebrafish, L-lamprey

² Previous evidence from human POI cases or GWAS of age at natural menopause ³Z score for missense variants and observed/expected (90% confidence intervals) for loss of function variantsgnomAD.⁵⁹ A Z score >3 indicates a gene constrained for missense variants and an upper bound 90% confidence interval <1 indicates a gene constrained for loss of function variants.

⁴ DAVID Gene Sets: 1-oogenesis/spermatogenesis, 5-male gonad development, 7-transcription/translation/DNA binding, 9-regulation of gene expression, 11-growth factor/cytokine/TGFβ, 13-chromatin binding, 16-meiosis/DNA repair/homologous recombination, 18-embryo development, 25-extracellular to cytoplasmic signaling, 32-protein kinase/phophorylation, 34-cell division/meiosis, 40-cell proliferation/DNA damage, 41-vasoactivity/hormone regulation. Also see Table 4. Other known biologic functions have been added for genes that were not found in DAVID.

Table 3. Candidate variants in genes from pathways with functional models

Gene	Chr Loc atio n	Coding Change	Protei n Chan ge	Zyg osit y	Conseq uence	gn om AD All ele Fre qu enc y	Con serv atio n ¹	PO I ID	Pri ma ry- 1 or Sec ond ary -2	Ref ere nce 2	Z Sc or e or Ob s/e xp	Gene Set ⁴
FA NC D2	3:100 8476 3		p.Leu3	Het ⁵	Frameshi ft	0.0 000 086 6/	NA ⁶	IP OF 33	(Ag e yrs)	138	0.7 1 (0. 58-	7,16,34, 40
KI T		c.919dupC	07Prof sTer20	Het	Missense	0.0 000 867	MCX			139	0.8 9) 2.5 8	1,7,9,11 ,16,25,3 2,40
	4:555 9755 0	c.2198C> T	p.Pro7 33Leu			0.0 000 738		FP OF 23	1 (19)			
CA SP 3	4: 1855 5649 5	c.84_130d elCTCTG GAATAT.	p.Ser2 9Glyfs Ter7	Het	Frameshi ft	0.0 000 174 / 0.0 000 295	NA	13 42 9X 45	2 (40)	140	0.3 (0. 15- 0.6 9)	7,11,16, 25,32,4 0
SK P2	5: 3615 3055	c.197dupC	p.Arg6 7Thrfs Ter10	Het	Frameshi ft	Nov el	NA	NI H7 10		141	0.1 3 (0. 06- 0.3 3)	7,11,16, 32,34,4 0
	5:361 7047 5	c.701G>A	p.Arg2 34Gln	Het	Missense	0.0 000 086 8 / 0.0	MZ	IP OF 9		141	1.9	

⁵Homo = homozygous, Het = heterozygous

⁶NA = not applicable, i.e. not identified

⁷Confirmed by Sanger Sequencing

⁸Expressed in superovulated mouse oocytes (Supplementary Table 9)

		T	1		T					1		1
						000						
						073						
						8						
NI	5:369			Het	Missense	Nov	NA	NI		142	5.5	7,11,16,
PB	8487					el		H8			7	34,40
L	9:A:							97				,
	T		p.Asn5									
	1	c.1597>T	33Tyr									
	5:	C.137771	331 yr	Het	Missense	Nov	NA	13	2	142	5.5	
	3700			Tiet	Wiisselise	el	IVA	42	(29,		7	
						CI		9X			/	
	0554							9A 66	30)			
								and				
								13				
								42				
		c.3384T>	p.His1					9X				
		G	128Gln					67				
AN							NA	IP			0.6	None
KR								OF			7	Meiosis
D3								47			(0.	_
1						0.0					53-	Double
						001					0.8	strand
	5:		p.Gln1			76 /					7)	break
	7440		479Thr			0.0						accessor
	0949		fsTer1		Frameshi	002				143,1		y
	07.17	c.4434dup	2	Het	ft	75				44		protein
RA		c. 113 Taup		Het	Frameshi	Nov	NA			19	0.7	7,13,16,
D5				Tict	ft	el	IVA				(0.	25,34,4
$\begin{vmatrix} DJ \\ 0 \end{vmatrix}$	5:131	c.1200_12			11	CI		NI			56-	0
0	9245	01delT>T						H8				U
											0.8	
	26	GA		TT 4	G.	NT A	D.T.A	30		19	7)	
				Het	Stop	NA	NA				0.7	
	- 101				Gain	/		**			(0.	
	5:131					0.0		IP			56-	
	9728	c.3454C>	p.Arg1			000		OF			0.8	
	71	T	152Ter			147		39		145	7)	
GJ	6:			Het	Missense		MCX	13		145	1.2	7,9,11,1
<i>A1</i>	1217						ZL	42			8	6,18,25,
	6852		p.Phe1			Nov		9X	2			32,40,4
	9	c.536T>A	79Tyr			el		50	(21)			1
MI	7:761			Het	Missense	Nov	MCX	11	2	146	0.4	7,34
OS	3260					el	Z	89	(25)		9	
								6X			(0.	
								11			35-	
		c.1154C>	p.Ser3								0.7	
		A	85Tyr)	
			00131								/	
FZ	11:86			Het	Missense	0.0	MCX	11		147	0.7	7,11,25,
D4	6630		p.Ile25	1101	14115501150	0.0	ZL	89	2		3	32,40
DŦ	32	c.766A>G	6Val			79 /		6X	(37)			32,70
	24	5.700A/U	ovai			171		0/1	(JI)			

	1	T	1	1	T	_		ı		1		
						0.0		13				
						006						
						46						
MR						0.0	NA				0.6	7,16,34,
E1						000					6	40
1						463					(0.	
						/					44-	
	11:94					0.0		NI			0.8	
	1804	c.1714G>	p.Arg5			000		H2		19,14	4)	
	54	A	72Ter	Het	Stop gain	718		25		8		
				Het	Missense	0.0	MCX				0.1	
						000	ZL	PP			3	
	11:94					086		OF				
	2048		p.Leu2			9/		10		19,14		
	67	c.718C>G	40Val			NA		5		8		
ML	14:75	C.710C>G	70 V a1	Het	Frameshi	Nov	NA	NI		149	0.4	7,16,40
<i>H3</i>	4856			1101	ft	el	11/1	H7			1	7,10,40
113	11		p.Gln1		11	CI		68			(0.	
	11		388Ser					00			29-	
		c.4162del	fsTer1								0.5	
	1 4 7 7	С	6	TT .	3.6	0.0	MON) TT		149	9)	
	14:75			Het	Missense	0.0	MCX	NI			0.7	
	5156					000	ZL	H8			4	
	43					436		49				
						/						
						0.0						
			p.Ile23			000						
		c.716T>G	9Ser			591				150,1		
TD				Het	Stop	0.0	NA	NI		51	0.4	1,7,16,3
RD					Gain	000		H2		31	9	4
9						228		25			(0.	
	14:					/					38-	
	1044					0.0					0.6	
	3694		p.Ser2			000					5)	
	5	c.833C>G	78Ter			199						
NU				Het	Stop		NA	IP		152,1	1.2	5,7,11,4
PR					Gain			OF		53	9	0
1								21			(0.	
	16:										52-	
	2854										1.9	
	9371		p.Ser9			Nov					1)	
		c.272C>G	1Ter			el						
ВС		3 - 3 - 3 - 3					NA			154	0.1	5,7,11,1
L2											5	6,25,32,
				hete	FRAME						(0.	34,40
	18:		p.Ala4	rozy	SHIFT_			NI			05-	51,10
	6098		5Argfs	gou	VARIA	Nov		H7			0.7	
	5767	c.132dupC	Ter108	S	NT	el		27			1)	
ER	19:45	c.2041C>	p.Asp6	· ·	111	0.0	MXZ	13	2	19,15	0.3	7,9,11,1
CC	8557	T	81Asn	Het	Missense	000	L	42	(40)	5	8	6,18,34,
	0221	1	011/2011	1101	14119901190	000	ட	+∠	(+0)		U	0,10,54,

2	69					260		9X				40
						/		18				
						0.0						
						000						
						147						
PC						NA	MCX	13	2		2.4	7,11,13,
NA						/	ZL	42	(20)		7	16,34,4
						0.0		9X				0
	20:51		p.Ser4			000		37				
	0032		2Leu			074						
	0	c.125G>A		Het	Missense	9				156		
AD						0.0	MCX	13		157	0.6	7,11,16,
AM						001	ZL	42			7	25
TS						01 /		9X				
1	21:					0.0		20				
	2821		p.Ala1			001						
	6862	c.412G>T	38Ser	Het	Missense	09			2	150		
US						0.0	MCX			158	z=	7,11,16,
P9						000	Z				6.4	25,34,4
X	X:					173		NI			1	0
	4099		p.Arg1			/		Н6				
	6058	c.437G>A	46Lys	Het	Missense	NA		34		158		
	X:41						MCX	NI		136	6.4	
	0274	c.2639T>	Leu87			Nov	ZL	H9			1	
	59	A	5His	Het	Missense	el		32		158		
							MCX	13		130	6.4	
	X:41	20051	4 00				ZL	42			1	
	0298	c.2996A>	Asn99	TT -) (°	Nov		9X	2			
	41	G	9Ser	Het	Missense	el	MON	39	(28)	158	<i>c</i> 4	
			TD 1			0.0	MCX				6.4	
	V.		p.Tyr1			000	Z	NIT			1	
	X:	- 2002 As	268Cy			087		NI				
	4104	c.3803A>	S	Hat	Missansa	5 /		H8				
AT	7363 X:	G		Het	Missense	NA	MCV	02 FP		159,1	3.1	17111
AT		a 5065Th	Th::100	Het	Missense	Nov	MCX		1	60	3.1	1,7,11,1
RX	7684	c.5965T>	Thr198			el		OF	1 (20)			6,34,40
	9311	C	9Ala					35	(29)			

¹ Conservation – M-mammals including rhesus, mouse, dog, elephant, C-chicken, X-Xenopus tropicalis, Z-zebrafish, L-lamprey

² Previous evidence from human or animal models

³Z score for missense variants and observed/expected (90% confidence intervals) for loss of function variantsgnomAD.⁵⁹ A Z score >3 indicates a gene constrained for missense variants and an upper bound 90% confidence interval <1 indicates a gene constrained for loss of function variants.

⁴ DAVID Gene Sets: 1-oogenesis/spermatogenesis, 5-male gonad development, 7-transcription/translation/DNA binding, 9-regulation of gene expression, 11-growth factor/cytokine/TGFβ, 13-chromatin binding, 16-meiosis/DNA repair/homologous recombination, 18- embryo development, 25-extracellular to cytoplasmic signaling, 32-protein kinase/phophorylation, 34-cell division/meiosis, 40-cell proliferation/DNA damage, 41-

vasoactivity/hormone regulation. Also see Table 4. Other known biologic functions have been added for genes that were not found in DAVID.

⁵Homo = homozygous, Het = heterozygous

⁶NA = not applicable, i.e. not identified

⁷Expressed in superovulated mouse oocytes (Supplementary Table 9)

⁸Confirmed by Sanger Sequencing

Table 4. Enhanced biological pathways or clusters in women with POI compared to controls.

Cluster 3. Biological Process	# Da mag ed Gen es Cas es POI	# Dama ged Gene s Cases Phen otypi c Abno rmalit y	# Da mag ed Gen es Con trols POI	# Dama ged Gene s Contr ols Phen otypi c Abno rmalit y	Total Numb er of Genes in Categ ory	Cases: Contro Is POI p value ^a	Cases: Contro ls Phenot ypic Abnor mality p value	Cases: Contro Is POI p value ^c _F	Cases: Contro ls Phenot ypic Abnor mality p value d F DR	Log ₂ Ratio <i>p</i> values _{FD} R Phenoty pic Abnorm ality/PO I
7. Transcription/ Translation/D	120	95	46	43	740	0.0000	0.0000	0.0000	0.0001	8.4
NA Binding 40. Cell Proliferation/D NA Damage	178	138	92	77	830	0.0000	0.0000	0.0000	0.0003	6.1
16. Meiosis/DNA Repair/Homol ogous Recombination	70	56	31	32	351	0.0000	0.0069	0.0008	0.029	5.0
41. Vasoactivity/H ormone						0.0000		0.0003		
Regulation 11. Growth Factor/Cytokin e/TGFβ	87	66	36	29	75 474	0.0000	0.0013	0.0000	0.0082	3.8
9. Regulation of Gene Expression	49	35	24	23	123	0.0023	0.074	0.011	0.14	3.6
18. Embryo Development 25.	23	16	4	3	61	0.0001 6	0.0022	0.0014	0.011	3.0
Extracellular to Cytoplasmic Signaling	44	33	15	12	284	0.0001	0.0012	0.0011	0.0082	2.9
1. Oogenesis/Spe rmatogenesis	13	8	3	3	91	0.011	0.11	0.035	0.19	2.4
34. Cell Cycle/Meiosis/ Nuclear Membrane	55	35	28	19	213	0.0020	0.020	0.011	0.057	2.4

5. Male Gonad										
Development	11	8	2	3	31	0.011	0.11	0.036	0.19	2.4
13. Chromatin										
Binding	11	13	1	4	58	0.0032	0.025	0.015	0.067	2.2
32. Protein										
Kinase/Phosph										
orylation	57	33	28	16	244	0.0011	0.011	0.0081	0.035	2.1

^a Fisher exact test *p* value for the number of damaged genes in the biological category found using GEM with the term POI in cases compared to controls. ^b Fisher exact test *p* value for the number of damaged genes in the biological category found using GEM with the term phenotypic abnormality in cases compared to controls. ^c Fisher exact test *p* value corrected for the false discovery rate for the number of damaged genes in the biological category found using GEM with the term POI in cases compared to controls. ^d Fisher exact test *p* value corrected for the false discovery rate for the number of damaged genes in the biological category found using GEM with the term phenotypic abnormality in cases compared to controls.

Table 5. Variants in candidate genes and candidate pathways with no previous model for

primary ovarian insufficiency.

Gen e	Chr Loc atio n	Coding Change	Protein Chang e	Zy go sit y	Cons eque nce	gno mA D Allel e Fre que ncy	Cons ervat ion ¹	PO I Ag e	Pri mar y-1 or Sec ond ary- 2 (Ag e yrs)	R e f	Z sco re or Ob s/e xp ²	Gene Set ³
MU TYH 6	1:45 7972 30	c.1103- 2A>G	NA ⁴	Het 5	Splice accept or	0.00 0031 2 / 0.00 0019 6	MCX Z	NI H7 5			0.88 (0.6 6- 1.19	16
	1:45 7991 08	c.241C>T	p.Arg10 6Trp	Het	Misse nse	0.00 0038 6 / 0.00 0039	MCX Z	NI H7 01			0.21	
<i>RPL</i> 5 ⁶	1:93 3030 32	c.547T>G	p.Tyr18 3Asp	Het	Misse nse	Nov el	MCX ZL	IPO F29			1.9	7,16,2 5,34,4 0
PR MT6	1: 1076 0015 3	c.819dup	p.Arg27 4AlafsT er146	Но	Frame shift	NA / 0.00 0007 473	NA	IPO F15		16 1	0.47 (0.2 5- 0.92	7
CH D1L 6	1: 1467 4044 8	c.998delC	p.Pro333 ArgfsTe r10	Het	Frame shift	Nov el	NA	134 29 X2 2	2 (37)	16 2	0.04 (0.8 3- 1.03	16
	1: 1467 5707 8	c.1937_194 1delAAAG A	p.Lys64 6ThrfsT er22	Het	Frame shift	0.00 0038 7 / 0.00 0026 1	NA	134 29 X8	2 (18)	16 2	0.04 (0.8 3- 1.03	
TDR KH	1: 1517 4724 3	c.1574_157 5delCT	p.Thr52 5ArgfsT er27	Het	Frame shift	0.00 0109 / 0.00 0177	NA	134 29 X3 8	2	89, 90	0.29 (0.1 7- 0.52)	1,25,3 4,40

CEN	1:21		p.Ala28				MC(n	IPO			-	7,34,4
PF^6	4830 419	c.8629G>C	77Pro	Ho mo	Misse nse	Nov el	ot XL)	F24			0.03	
TAR BP1	1: 2345						NA	NI H9			0.66	7
6 BP 1	2954		p.Val14					14			(0.5 2-	
	0	c.4286_428 7insT	30Argfs Ter33	Het	Frame shift	Nov el					0.84	
APL	2:68	711151	10133	Tiet	SIIII	Nov	MC	134	2	16	0.1	16
F^6	6949 42		p.Arg27		Misse	el		29 X5	(38)	3		
		c.79C>T	Cys	Het	nse			2				
	2: 6871					0.00	NA	IPO F26			1.1 (0.8	
	7330					84 /		120			1-	
		c.106_107d	p.Lys36 GlufsTer		Frame	0.00 0007					1.53	
		elAA	10	Het	shift	49						
	2: 6871					NA / 0.00	M	IPO F16			0.1	
	7350		p.His42		Misse	0.00		110				
	2:68	c.125A>T	Leu	Het	nse	3	NIA	134	2		1.1	
	7299					0.00 0085	NA	29	2		(0.8	
	01		n I au 72			8 / 0.00		X3 5			1-	
		c.210_213d	p.Leu72 SerfsTer		Frame	0.00		3			1.53	
II/D	2	upTCAG	24	Het	shift	5	NIA	124	2	87		7.16
WD $R33^6$	2: 1284					nove 1	NA	134 29	(38)		0.13 (0.0	7,16
,7,8	6739	2246 224	p.Ala11		Б			X1			8-	
	2	c.3346_334 7insGA	16Glyfs Ter166	Het	Frame shift			1			0.21	
RNF	2.10			Het	Stop	Nov	NA	NI			0.84	16,34
168 ⁶	3:19 6214		p.Arg16		Gain	el		H9 26		16	(0.6	
GD7	335	c.493G>A	5Ter			0.00	MON	104	2 (27	4	1.2)	7.05
CPZ						0.00 0001	MCX Z	134 29	2 (37 and		4,43	7,25
						52 /		X2	39)			
						0.00 0055		8 and				
	4.2					1		134				
	4:86 0322		p.Arg16		Misse			29 X7				
	1	c.493C>T	5Trp	Het	nse			1				
BO D1L	4:		p.Glu33			0.00 0022	NA	NI H6			0.17 (0.1	16
$1^{6,8}$	1361	c.1009_101	7ArgfsT		Frame	2 /		33		97	1-	
	5981	2delGAAA	er32	Het	shift	0.00				9/	0.25	

						0029)	
CD K7	5: 6853 1230	c.78_79delT T	p.Tyr27 GlnfsTer	Het	Frame shift	5 0.00 0008 66 / NA	NA	118 96 X1 5	2 (31)	16 5	0.64 (0.4 2- 1.02	7,34,4
BDP 1 ⁶	5: 7085 6038	c.7471delT	p.Ser249 1ArgfsT er20	Het	Frame shift	Nov el	NA	FP OF 19	1			7
POL K ^{6,7}	5: 7489 2232	c.1714C>T	p.Arg57 2Ter	Het	Stop Gain	0.00 0117 / 0.00 0078 5	NA	134 29 X2 4	2 (40)	16 6	0.62 (0.4 6- 0.87	16
DC P2 ^{6,7}	5: 1123 4371 0	c.1018C>T	p.Gln34 0Ter	Het	Stop Gain	0.00 0034 7 / NA	NA	134 29 X1 3	2 (36)	16 7,1 68	0.2 (0.1 - 0.41)	7
<i>NU P43</i> ⁶	6:15 0067 167	c.141_151d elGTCTAT TGGAG	p.Trp47 Ter	Het	Stop Gain	0.00 0017 3 / 0.00 0014 7	NA	NI H8 32		16 9,1 70	0.51 (0.3 2- 0.84)	7,34
BRA T1 ⁶	7: 2584 678	c.294dupA	p.Leu99 ThrfsTer 92	Het	Frame shift	0.00 0252 / 0.00 0234	NA	NI H8 59 and 134 29 X3 6	2 (X,3 6)	17	0.71 (0.5 1- 0.99)	16,40
CAS TOR 3 (GA TS) ⁷	7: 9982 1688	c.218- 15_227dup TGTGTCT.	p.Ser77 ValfsTer 52	Het	Frame shift	0.00 0017 5 / 0.00 0007 39	NA	134 29 X3 8	2	56	0.55 (0.2 7- 1.25	None POI
NC AP G2 ⁶	7:15 8455 043	c.1830_183 1delAC	p.Leu61 1ValfsT er23	Het	Frame shift	Nov el	NA	134 29 X3 1	2 (40)	17 2	0.18 (0.1 1- 0.31	7,34
<i>NP M</i> 2 ^{6,} _{7,8}	8: 2188 2984	c.97dupA	p.Arg33 LysfsTer 90	Het	Frame shift	0.00 0030 9 /	NA	118 96 X1	2 (34)	92	0.51 (0.2 9-	7,11,1 3,40

	1				1			T -	1			
						0.00		8			0.95	
						0006)	
						52						
						all						
						afric						
						an						
						0.00						
						0203						
PIW	8:22			Het	Stop	0.00	NA	NI		88,	0.42	1,16,3
$IL2^8$	1369			1100	gain	0023	IVA	H7		89	(0.3	4,40
ILZ	12		p.Arg5T		gain	/		90			(0.5	4,40
	12					0.00		90			0.6)	
		12C T	er			0.00					0.6)	
ZVE		c.13C>T			-	0026	27.4	104	2		0.26	7.16
ZNF					Frame	NA/	NA	134	2		0.36	7,16
572	8:				shift	0.00		29	(35)		(0.2	
	1259		p.Ala64			0071		X2			-	
	8993		SerfsTer			7		0			0.72	
	2	c.188dupC	9	Het)	
TON					Frame	Nov	NA	NI		17	0.51	7
SL^6	8:				shift	el		H9		3,1	(0.3)	
	1456		p.Asp58					37		74	8-	
	6228		3ThrfsT								0.69	
	2	c.1747delG	er60	Het)	
HA				Het	Frame	Nov	NA				0.72	34
US6				1100	shift	el	1,11				(0.5	
6	9:		p.Arg25		Sint			NI			4-	
	1908	c.755_758d	2LysfsT					H8		17	0.96	
	2982	elGAGA	er15					00		5)	
VCP	9:	CIOAGA	CITS	Het	Misse	0.00	MCX	134	2	94	5.41	7,11,1
6,7,8	3506			1100		0.00	Z	29	2		3.41	6,40
	8336				nse	/NA	L	X6				0,40
	8330					/1 NA						
								6				
								and				
								134				
								29				
			p>Thr14					X6				
		c.41G>A	Ile					7				
HN				Het	Misse	Nov	MCX	134	2		3.99	7,34,4
RNP	9:86				nse	el	Z	29				0
K^6	5868		p.Pro311					X6		17		
	18	c.928G>A	Leu					1		6		
CPE							NA			17	0.07	7,16,4
$B3^6$										7	(0.0)	0
	10:		p.Pro87					NI			3-	
	9399		LeufsTe		Frame	nove		H8			0.23	
	9849	c.258delT	r33	Het	shift	1		78)	
C10	10:			Het	Frame	0.00		134	2	N	0.86	7
	1281		p.Ile407		shift	0114		29	(38)	A	(0.6	
0^6	9254	c.1219_122	LysfsTer		2222	/		X4		•	2-	
	9	0insAA	28			0.00		9			1.21	
	/	J11157 1/ 1	20			0.00		1	1		1.41	

						0071)	
						8					,	
						0.00	27.	101			0.00	
TSG 101 ⁶	11:1					0.00	NA	134	2		0.23	7,11,1
101	8503 395		p.Ile288			0008 67 /		29 X3			(0.1 2-	6,25,3 2,40
	393	c.863_864d	ArgfsTe		Frame	NA		8			0.48	2,40
		elTA	r8	Het	shift)	
NAP				Het	Stop	0.00	NA	134	2		0.19	7
$1L4^{6}$					Gain	0478		29	(20,		(0.0)	
,,						/		X3 4	X)		1- 0.39	
	11:					0.00 0485		and)	
	2999					0403		NI			,	
	567		p.Ser7Te					Н		17		
		c.20C>G	r					708		8		
NAN						0.00	NA	118	2	17 9	0.54	7
OG NB^7	12:		n Aral6			0012 9 /		96 X1	(39)		(0.2 801.	
IVD	7923	c.486_490d	p.Arg16 4AlafsT		Frame	NA		2			12)	
	084	elCAAGA	er2	Het	shift	1111		_			12)	
NIN						0.00	Not	118	1		0.33	7,16
6,7	14:5					0124	conser	96				
	1224		p.Met10	TT.	Minn	/	ved	X2				
	657	c.3109T>C	31Val	Ho mo	Misse nse	0.00 0124						
		C.31091/C		Het	Stop	Nov	NA	118	2		0.32	
				1100	Gain	el	1,112	96	(32)		(0.2	
	14:							X8		10	5-	
	5128	1.60 T	p.Gln6T							18	0.43	
OR	8759	c.16C>T	er				NA	134	2		0.84	7,16,2
$C6^6$							INA	29	(40)		(0.5	5,34,4
	16:		p.Arg29					X6	(10)		3-	0
	4672		AlafsTer		Frame	Nov		3		18	1.39	
	4920	c.84dupG	42	Het	shift	el			_	96)	
LLG	17:			Het	Stop	0.00	NA	134	2	90	0.35	7,25,4
$L1^6$	1813 8789				Gain	0008 67 /		29 X2	(40)		(0.2 4-	0
	0/07					0.00		6			0.53	
			p.Trp43			0007)	
		c.1290G>A	0Ter			36						
BRI				Het	Stop	0.00	NA	118	2		0.59	7,11,1
$P1^6$					Gain	0007		96 V0	(39)		(0.4	6
	17:5					73 / 0.00		X9			6- 0.79	
	9878		p.Arg35			0.00				18)	
	688	c.1066G>A	6Ter			1				2	,	
USP	17:	c.2952_297	p.Asp98	Но	Frame	0.00	NA	134	2	85,	0.35	7
$36^{7,8}$	7679	7delAGAT	5LeufsT	mo	shift	0018		29	(39)	18	(0.2	

EEF 26 RUV BL2 6	19:3 9842 03 19: 4951 4507 20:2 5462 625	c.149C>T c.941G>A c.1782_178 8delACGG CAG	p.Arg50 Gln p.Arg31 4Gln p.Arg59 4SerfsTe r19	Het	Misse nse Misse nse	6 / NA Nov el 0.00 0017 6 / 0.00 0051 7	MCX ZL MCX	X1 2 IPO F21 134 29 X6	2 (40)	18 4	4- 0.52) 4.88 3.11	7,25,4 0 7,16
RUV BL2 6	9842 03 19: 4951 4507 20:2 5462	c.941G>A c.1782_178 8delACGG	p.Arg31 4Gln p.Arg59 4SerfsTe		nse Misse	0.00 0017 6 / 0.00 0051	ZL MCX	F21 134 29 X6	(40)		3.11	7,16
RUV BL2 6	19: 4951 4507 20:2 5462	c.941G>A c.1782_178 8delACGG	p.Arg31 4Gln p.Arg59 4SerfsTe		nse Misse	0.00 0017 6 / 0.00 0051	MCX	134 29 X6	(40)		0.82	7,16
BL2 6	4951 4507 20:2 5462	c.1782_178 8delACGG	p.Arg59 4SerfsTe	Het		0017 6 / 0.00 0051		29 X6	(40)		0.82	
o NIN	4951 4507 20:2 5462	c.1782_178 8delACGG	p.Arg59 4SerfsTe	Het		6 / 0.00 0051	NA	X6	1			34
	4951 4507 20:2 5462	c.1782_178 8delACGG	p.Arg59 4SerfsTe	Het		0051	NA					34
	20:2 5462	c.1782_178 8delACGG	p.Arg59 4SerfsTe	Het			NA			4		34
	5462	8delACGG	4SerfsTe				NA					34
	5462	8delACGG	4SerfsTe					OI.	(1 7)			
					1			19	(1)		9-	
	020	0.10		Het	Frame shift	Nov el					1.09	
SAM							NA	134	2		0.67	7,11,1
HD1						0.00		29 X1	(38)		(0.4 9-	
						0008		1			0.94	
	20:3					65 / 0.00)	
	5555		p.Arg22		Stop	0014						
	623	c.658G>A	0Ter	Het	Gain	7	NA	118	2		0.67	
							1,12	96	_		(0.4	
	20:3 5555	c.647_648d	p.Met21		Frame	Nov		X2 4			9- 0.94	
	633	elCAT>C	6fsTer1	Het	shift	el				88,)	
PIW IL3 ^{7,}	22:2 5124	c.1933-		Het	Splice site	0.00 0797	NA	134 29	(20)	18	0.96 (0.7	1,7,16 ,34,40
8	021	7_1933-				/		X3	(==)	5	7-	,- ,, ,
		2delACTT AA	NA			0.00 0647		7			1.22	
					Stop	0.00	NA	134	2	88, 18	0.96	
					Gain	0008 69 /		29 X3	(20)	5	(0.7 7-	
	22.2					0.00		7			1.22	
	22:2 5152		p.Gln12			0014 8)	
G3.5 :	652	c.376C>T	6Ter	Het			27.	440			0.0:	
	X:						NA					7,16
1	1286				a			X1	(-0)	18	2-	
	2099	c.2217G>A	p.Lys73 9=	Het	Splice site			0		6	0.14	
SMA RCA 1	652 X:	c.376C>T	•	Het	Splice	Nov el	NA	118 96 X1 0	2 (16)	18	0.04 (0.0 2- 0.14	7,16

¹ Conservation – M-mammals including rhesus, mouse, dog, elephant, C-chicken, X-Xenopus tropicalis, Z-zebrafish, L-lamprey

²Z score for missense variants and observed/expected (90% confidence intervals) for loss of function variantsgnomAD.⁵⁹ A Z score >3 indicates a gene constrained for missense variants and an upper bound 90% confidence interval <1 indicates a gene constrained for loss of function variants.

³ DAVID Gene Sets: 1-oogenesis/spermatogenesis, 5-male gonad development, 7-transcription/translation/DNA binding, 9-regulation of gene expression, 11-growth factor/cytokine/TGFβ, 13-chromatin binding, 16-meiosis/DNA repair/homologous recombination, 18-embryo development, 25-extracellular to cytoplasmic signaling, 32-protein kinase/phophorylation, 34-cell division/meiosis, 40-cell proliferation/DNA damage, 41-vasoactivity/hormone regulation. Also see Table 4. Other known biologic functions have been added for genes that were not found in DAVID.

⁴NA = not applicable, i.e. not identified

⁷Confirmed by Sanger Sequencing

⁵Homo = homozygous, Het = heterozygous

⁶Expressed in superovulated mouse oocytes (Supplementary Table 9)

⁸Functional support from *D. melanogaster* model

Table 6. Ovary and fertility phenotypes in *D. melanogaster* RNAi knockdown in ovaries/germline.

Human Gene	Fly Ortholog	Ovary Defect	Egg Defect ¹	Hatchability ²	Fertility ³
USP36	Scny	atrophic	No eggs		infertile
VCP	TER94	atrophic	No eggs		infertile
WDR33	wdr33	atrophic	No eggs		infertile
PIWIL3	piwi	atrophic	No eggs		infertile
NPM2	NIp	atrophic	No eggs		infertile
LLGL1	l(2)gl	normal	normal	~20%	~1%
BOD1L1	BOD1	normal	normal	normal	~50%
DCP2	DCP2	normal	normal	normal	normal
TDRKH	papi	normal	normal	normal	normal
SMRCA/CHDL1	Iswi	normal	normal	normal	normal
TTLL5	TTLL5	normal	normal	normal	normal
CPEB3	orb2	normal	normal	normal	normal
CDK7	Cdk7	Normal ⁴	normal	normal	normal
BRIP1	CG4078	Normal ⁴	normal	normal	normal
NIN	Bsg25D	normal	normal	normal	normal
NAP1L4	Nap1	normal	normal	normal	normal
BRAT1	CG7044	normal	normal	normal	normal

¹Number of eggs laid in first 8 hrs after mating

²Number of progeny hatched from eggs counted, "--" indicates no value because no eggs were laid.

³Total progeny count 10 days post mating

⁴CDK7 and BRIP1 displayed inconsistent minor ovary defects, but fertility was completely normal

Figure 1. Three examples of enriched pathways in the POI data set as determined by the permutation tests in cases (upper panels) and controls (lower panels). Enriched pathways that encompassed novel POI genes (Table 5) included: A) Transcription/Translation/DNA binding, B) Meiosis/DNA Repair/Homologous Recombination and C) Cell Division/Meiosis, compared to D) Housekeeping Genes. The number of damaged genes from the target gene list in the pathways of interest (red arrow) is compared to the distribution of damaged genes in random gene lists of equal number to the lists of interest (gray bars), burden-matched control genes (pink arrows) and housekeeping genes (green arrows). The burden-matched genes and housekeeping genes are not significantly enriched for any gene set. *p* values are controlled for the false discovery rate.

Figure 2. Candidate genes in women with POI. Variants in a number of genes involved in chromosome pairing and DNA damage and repair are involved in meiosis. The figure depicts candidate genes that are involved in chromosome movement, double strand breaks, end resection, double strand break repair, crossovers and dissociation and resolution of Holliday junctions. Members of the nuclear pore complex (NUP43) play a role in chromosome movement and organization. After DNA replication (*ORC6*), the synaptonemal complex pairs homologous chromosomes (*PSMC3IP*) loaded with condensin and cohesion complex proteins (*STAG3*, *REC8*, *NIPBL*) and connects the synaptonemal complex to DNA repair proteins (*SYCE1*). During recombination, double strand breaks form (*ATM*, *ANKRD3*, *PIF1*), ends are resected (*BRCA1*, *SAMHD1*, *BOD1L1*), and crossovers occur (*HFM1*) through strand invasion (*PSMC3IP*, *MND1*, *RAD51*). Subsequently, DNA double strand break repair (*CHD1L*, *POLG*, *POLK*, *MSH6*, *PCNA*, *NUPR1*, *APLF*, *NBN*, *RAD50*, *RUVBL2*, *MRE11*), DNA repair (*CDK7*, *MLH3*, *PRMT6*, *HELQ*, *TONSL*), strand annealing (*RECQL4*) and repair via homologous recombination (*BRCA2*, *BRIP1*, *FANCD2*, *HELQ*, *FANCM*, *FANCF*, *BLM*, *MCM9*, *USP36*) take

place. Kinetochore/chromosome assembly, orientation and segregation (*HAUS6*, *CENPF*, *NUP43*, *NCAPG2*, *LLGL1*, *NINL*, *ATRX*) follow recombination.

Supplementary Table 1. Annotation clusters identified using the Database for Annotation, Visualization and Integrated Discovery (DAVID). Data were organized into 47 clusters with enrichment scores of >2.

Supplementary Table 2. Housekeeping genes. Genes that are constantly and uniformly expressed over many developmental and adult time points in 16 tissue types were chosen as housekeeping genes to examine enrichment.

Supplementary Table 3. PCR primers used to analyze gene expression in super ovulated mouse oocytes using RTPCR.

Supplementary Table 4. Samples removed by Peddy for very low heterozygosity and low coverage.

Supplementary Table 5. Related subjects identified by Peddy.

Supplementary Table 6. Ancestry identified by PCA plot and projection onto 1000 genomes data.

Supplementary Table 7. GEM results for all subjects. The GEM results for all genes with a GEM score greater than 0 are presented.

Supplementary Table 8. Oocyte expression. RTPCR was performed in superovulated mouse oocytes for gene targets with no previous functional studies.

Supplementary Table 9. Genes chosen for RNAi knockdown in a *D. melanogaster* model with Bloomington *Drosophila* Stock Center Number (BDSC#).

Supplementary Figure 1. Quality control metrics for 283 POI cases.

Box whisker plots of the alignment statistics and vcf statistics for 283 cram and vcf files that passed QC metrics: A) Total number of reads per sample, B) Percentage of Aligned reads, C) Percentage of duplicate reads, D) Mean coverage per sample, E) Median coverage per sample, F) Percentage of Coverage over 20 bases, G) Number of SNPs per sample extracted from the Bcftools statistics, H) Number of Indels found per sample, and I) Average Depth per sample.

Supplementary Figure 2. Peddy analysis of 283 samples from the final VCF files of women with POI. A) The predicted sex was female for all cases. B) The proportion of heterozygous calls ranged from 0.12 to 0.18 at a median depth of 30 to 65. C) PCA projection of the 283 cases onto ancestry of 1000 Genomes data. The majority of subjects were of European ancestry as expected. D) Coefficient of relatedness between two samples plotted by sampling 25K sites in the genome and comparing the relatedness reported in the ped file to the relatedness inferred from the genotypes. Thus, five sib pairs were confirmed, along with grandparent-parent and parent-child relationships. E) Five pedigrees of relationships confirmed by Peddy and investigators.

Supplementary Figure 3-16. Enriched pathways in the POI data set as determined by the permutation tests in cases (upper left panels) and controls (lower left panels) and compared to data from the same pathways for the root phenotypic abnormality (upper right and lower right panels). The number of damaged genes from the pathways of interest (red arrow) is compared to the distribution of damaged genes in random gene lists of equal number to the lists of interest (gray bars), burden-matched control genes (pink arrows), and housekeeping genes (green arrows). The burden-matched genes and 16A) housekeeping genes are not significantly enriched for any gene set.

Supplementary Figure 17. PA-1 cells were transfected using PolyJet transfection reagent (SignaGen Laboratories, Rockville, MD) with WT eIF4ENIF1 or eIF4ENIF1 containing the c.603T>G variant created using the QuikChange II Site-Directed Mutagenesis kit (Agilent Technologies, Santa Clara, CA) into a pcDNA3.1(-) expression vector (Invitrogen, Carlsbad, CA) using the NEBuilder HiFi DNA Assembly Cloning Kit (New England Biolabs, Ipswich, MA). Stable cell lines were generated by selection of colonies resistant to 750 µg/ml G418 (Life Technologies, Carlsbad, CA). Cells were seeded at 3 x 10⁴ cells/well in an 8-well chamber slide. After 48 hours, cells were fixed with ice-cold 100% methanol for 5 minutes at room temperature (RT), followed by washing with PBST comprising 0.1% Tween-20 in 1x PBS (Fisher Scientific, Waltham, MA). Cells were blocked with 1% BSA and 22.52 mg/ml glycine (Fisher Scientific, Waltham, MA) in PBST for 30 minutes at RT and then incubated with an N-terminal antibody (Novus Biologicals, Centennial, CO) diluted in 1% BSA in PBST at 4°C overnight. After another wash with PBST, cells were labeled with an anti-rabbit Alexa Fluor 594 (Invitrogen, Carlsbad, CA) for 1 hour at RT, washed with PBST as before, counterstained with DAPI (Southern Biotech, Birmingham, AL), and mounted with glycerol mounting medium with DABCO (Electron Microscopy Sciences, Hatfield, PA). The Nikon fluorescent microscope was used for image acquisition. The c.603T>G variant, p.S201R, is located in the nuclear import signal of elF4ENIF1. The top panels show the N terminal elF4ENIF1 images with DAPI staining of the nucleus, while the bottom panels show the N terminal eIF4ENIF1 images. Compared to the A) wild type eIF4ENIF1, the B) S201R variant transfected cells demonstrated disorganized localization of *eIF4ENIF1* with increased intranuclear protein.

Supplementary Figure 18. *Drosophila melanogaster* phenotypes.

Hatchability and total fertility values are plotted for all genes tested by RNAi in *Drosophila*. P values for genes with significantly different phenotypic values are highlighted in red. N= 8-10 for all measurements. C= control; KD= RNAi knockdown

Supplementary Figure 19. Drosophila melanogaster ovarian phenotype.

Representative images of ovaries from RNAi knockdowns that produced atrophic ovaries and a control. All other RNAi knockdowns that produced normal ovaries appear identical to the control and are not shown.

References

- Welt, C. K. Primary ovarian insufficiency: a more accurate term for premature ovarian failure. *Clinical endocrinology* **68**, 499-509, doi:10.1111/j.1365-2265.2007.03073.x (2008).
- de Bruin, J. P. *et al.* The role of genetic factors in age at natural menopause. *Human reproduction* **16**, 2014-2018 (2001).
- 3 Treloar, S. A., Do, K. A. & Martin, N. G. Genetic influences on the age at menopause. *Lancet* **352**, 1084-1085, doi:10.1016/S0140-6736(05)79753-1 (1998).
- Snieder, H., MacGregor, A. J. & Spector, T. D. Genes control the cessation of a woman's reproductive life: a twin study of hysterectomy and age at menopause. *The Journal of clinical endocrinology and metabolism* **83**, 1875-1880, doi:10.1210/jcem.83.6.4890 (1998).
- Torgerson, D. J., Thomas, R. E. & Reid, D. M. Mothers and daughters menopausal ages: is there a link? *European journal of obstetrics, gynecology, and reproductive biology* **74**, 63-66 (1997).
- 6 Vegetti, W. *et al.* Inheritance in idiopathic premature ovarian failure: analysis of 71 cases. *Human reproduction* **13**, 1796-1800 (1998).
- Vries, L. D. *et al.* Exome sequencing reveals SYCE1 mutation associated with autosomal recessive primary ovarian insufficiency. *The Journal of clinical endocrinology and metabolism*, jc20141268, doi:10.1210/jc.2014-1268 (2014).
- 8 Caburet, S. *et al.* Mutant cohesin in premature ovarian failure. *The New England journal of medicine* **370**, 943-949, doi:10.1056/NEJMoa1309635 (2014).
- 9 Kasippillai, T. *et al.* Mutations in eIF4ENIF1 are associated with primary ovarian insufficiency. *The Journal of clinical endocrinology and metabolism* **98**, E1534-1539, doi:10.1210/jc.2013-1102 (2013).
- Wood-Trageser, M. A. *et al.* MCM9 mutations are associated with ovarian failure, short stature, and chromosomal instability. *American journal of human genetics* **95**, 754-762, doi:10.1016/j.ajhg.2014.11.002 (2014).
- 11 Katari, S. *et al.* Novel Inactivating Mutation of the FSH Receptor in Two Siblings of Indian Origin With Premature Ovarian Failure. *The Journal of clinical endocrinology and metabolism* **100**, 2154-2157, doi:10.1210/jc.2015-1401 (2015).
- AlAsiri, S. *et al.* Exome sequencing reveals MCM8 mutation underlies ovarian failure and chromosomal instability. *The Journal of clinical investigation* **125**, 258-262, doi:10.1172/JCI78473 (2015).
- Qin, Y., Jiao, X., Simpson, J. L. & Chen, Z. J. Genetics of primary ovarian insufficiency: new developments and opportunities. *Human reproduction update* **21**, 787-808, doi:10.1093/humupd/dmv036 (2015).
- Tucker, E. J., Grover, S. R., Bachelot, A., Touraine, P. & Sinclair, A. H. Premature Ovarian Insufficiency: New perspectives on genetic cause and phenotypic spectrum. *Endocrine reviews*, er20161047, doi:10.1210/er.2016-1047 (2016).
- Al-Agha, A. E. *et al.* Primary Ovarian Insufficiency and Azoospermia in Carriers of a Homozygous PSMC3IP Stop Gain Mutation. *The Journal of clinical endocrinology and metabolism* **103**, 555-563, doi:10.1210/jc.2017-01966 (2018).
- Ahmed, S. *et al.* Exome analysis identified a novel missense mutation in the CLPP gene in a consanguineous Saudi family expanding the clinical spectrum of Perrault Syndrome type-3. *J Neurol Sci* **353**, 149-154, doi:10.1016/j.jns.2015.04.038 (2015).
- Lourenco, D. *et al.* Mutations in NR5A1 associated with ovarian insufficiency. *The New England journal of medicine* **360**, 1200-1210, doi:10.1056/NEJMoa0806228 (2009).
- Heddar, A., Beckers, D., Fouquet, B., Roland, D. & Misrahi, M. A Novel Phenotype Combining Primary Ovarian Insufficiency Growth Retardation and Pilomatricomas With MCM8 Mutation. *The Journal of clinical endocrinology and metabolism* **105**, doi:10.1210/clinem/dgaa155 (2020).
- Tucker, E. J. *et al.* TP63-truncating variants cause isolated premature ovarian insufficiency. *Hum Mutat* **40**, 886-892, doi:10.1002/humu.23744 (2019).

- Patino, L. C. *et al.* New mutations in non-syndromic primary ovarian insufficiency patients identified via whole-exome sequencing. *Human reproduction* **32**, 1512-1520, doi:10.1093/humrep/dex089 (2017).
- Murray, A. *et al.* Common genetic variants are significant risk factors for early menopause: results from the Breakthrough Generations Study. *Human molecular genetics* **20**, 186-192, doi:10.1093/hmg/ddq417 (2011).
- 22 https://doi.org/10.1101/2021.01.11.20248322.
- Jaillard, S. *et al.* New insights into the genetic basis of premature ovarian insufficiency: Novel causative variants and candidate genes revealed by genomic sequencing. *Maturitas* **141**, 9-19, doi:10.1016/j.maturitas.2020.06.004 (2020).
- De La Vega, F. M. *et al.* Artificial intelligence enables comprehensive genome interpretation and nomination of candidate diagnoses for rare genetic diseases. *medRxiv*, 2021.2002.2009.21251456, doi:10.1101/2021.02.09.21251456 (2021).
- Hu, H. *et al.* VAAST 2.0: improved variant classification and disease-gene identification using a conservation-controlled amino acid substitution matrix. *Genetic epidemiology* **37**, 622-634, doi:10.1002/gepi.21743 (2013).
- Kennedy, B. *et al.* Using VAAST to Identify Disease-Associated Variants in Next-Generation Sequencing Data. *Current protocols in human genetics / editorial board, Jonathan L. Haines ...* [et al.] **81**, 6 14 11-16 14 25, doi:10.1002/0471142905.hg0614s81 (2014).
- Watkins, W. S. *et al.* De novo and recessive forms of congenital heart disease have distinct genetic and phenotypic landscapes. *Nat Commun* **10**, 4722, doi:10.1038/s41467-019-12582-y (2019).
- Werling, D. M. *et al.* An analytical framework for whole-genome sequence association studies and its implications for autism spectrum disorder. *Nature genetics* **50**, 727-736, doi:10.1038/s41588-018-0107-y (2018).
- Popat, V. B., Vanderhoof, V. H., Calis, K. A., Troendle, J. F. & Nelson, L. M. Normalization of serum luteinizing hormone levels in women with 46,XX spontaneous primary ovarian insufficiency. *Fertility and sterility* **89**, 429-433, doi:10.1016/j.fertnstert.2007.02.032 (2008).
- Kerber, R. A., O'Brien, E., Boucher, K. M., Smith, K. R. & Cawthon, R. M. A genome-wide study replicates linkage of 3p22-24 to extreme longevity in humans and identifies possible additional loci. *PLoS One* **7**, e34746, doi:10.1371/journal.pone.0034746 (2012).
- Smith, K. R. *et al.* Familial aggregation of survival and late female reproduction. *J Gerontol A Biol Sci Med Sci* **64**, 740-744, doi:10.1093/gerona/glp055 (2009).
- Malhotra, A., Cromer, K., Leppert, M. F. & Hasstedt, S. J. The power to detect genetic linkage for quantitative traits in the Utah CEPH pedigrees. *J. Hum. Genet.* **50**, 69-75, doi:10.1007/s10038-004-0222-8 (2005).
- Moriwaki, M. M., B.; Mosbruger, T.; Neklason, D.W.; Yandell, M.; Jorde, L.B.; Welt, C.K. POLR2C Mutations are Associated with Primary Ovarian Insufficiency in Women. *J Endocr Soc* 1, 162-173 (2017).
- Freed, D., Aldana, R. Weber, J.A., Edwards, J.S. The Sentieon Genomics Tools A fast and accurate solution to variant calling from next-generation sequence data. *bioRxiv* (2017).
- Faust, G. G. & Hall, I. M. SAMBLASTER: fast duplicate marking and structural variant read extraction. *Bioinformatics* **30**, 2503-2505, doi:10.1093/bioinformatics/btu314 (2014).
- Ewels, P., Magnusson, M., Lundin, S. & Kaller, M. MultiQC: summarize analysis results for multiple tools and samples in a single report. *Bioinformatics* **32**, 3047-3048, doi:10.1093/bioinformatics/btw354 (2016).
- Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor. *Bioinformatics* **34**, i884-i890, doi:10.1093/bioinformatics/bty560 (2018).
- Pedersen, B. S., Collins, R. L., Talkowski, M. E. & Quinlan, A. R. Indexcov: fast coverage quality control for whole-genome sequencing. *Gigascience* **6**, 1-6, doi:10.1093/gigascience/gix090 (2017).

- Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**, 2078-2079, doi:10.1093/bioinformatics/btp352 (2009).
- Li, H. A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. *Bioinformatics* **27**, 2987-2993, doi:10.1093/bioinformatics/btr509 (2011).
- Pedersen, B. S. & Quinlan, A. R. Who's Who? Detecting and Resolving Sample Anomalies in Human DNA Sequencing Studies with Peddy. *American journal of human genetics* **100**, 406-413, doi:10.1016/j.ajhg.2017.01.017 (2017).
- Flygare, S. *et al.* The VAAST Variant Prioritizer (VVP): ultrafast, easy to use whole genome variant prioritization tool. *BMC Bioinformatics* **19**, 57, doi:10.1186/s12859-018-2056-y (2018).
- Genomes Project, C. *et al.* An integrated map of genetic variation from 1,092 human genomes. *Nature* **491**, 56-65, doi:10.1038/nature11632 (2012).
- Lek, M. *et al.* Analysis of protein-coding genetic variation in 60,706 humans. *Nature* **536**, 285-291, doi:10.1038/nature19057 (2016).
- Jolly, A. *et al.* Exome Sequencing of a Primary Ovarian Insufficiency Cohort Reveals Common Molecular Etiologies for a Spectrum of Disease. *The Journal of clinical endocrinology and metabolism* **104**, 3049-3067, doi:10.1210/jc.2019-00248 (2019).
- Hantash, F. M. *et al.* FMR1 premutation carrier frequency in patients undergoing routine population-based carrier screening: insights into the prevalence of fragile X syndrome, fragile X-associated tremor/ataxia syndrome, and fragile X-associated primary ovarian insufficiency in the United States. *Genet. Med.* **13**, 39-45, doi:10.1097/GIM.0b013e3181fa9fad (2011).
- Fuentes Fajardo, K. V. *et al.* Detecting false-positive signals in exome sequencing. *Hum Mutat* **33**, 609-613, doi:10.1002/humu.22033 (2012).
- Coonrod, E. M., Margraf, R. L., Russell, A., Voelkerding, K. V. & Reese, M. G. Clinical analysis of genome next-generation sequencing data using the Omicia platform. *Expert Rev Mol Diagn* **13**, 529-540, doi:10.1586/14737159.2013.811907 (2013).
- Ng, P. C. & Henikoff, S. Predicting deleterious amino acid substitutions. *Genome research* **11**, 863-874, doi:10.1101/gr.176601 (2001).
- Adzhubei, I. A. *et al.* A method and server for predicting damaging missense mutations. *Nature methods* **7**, 248-249, doi:10.1038/nmeth0410-248 (2010).
- Schwarz, J. M., Rodelsperger, C., Schuelke, M. & Seelow, D. MutationTaster evaluates disease-causing potential of sequence alterations. *Nature methods* **7**, 575-576, doi:10.1038/nmeth0810-575 (2010).
- Pollard, K. S., Hubisz, M. J., Rosenbloom, K. R. & Siepel, A. Detection of nonneutral substitution rates on mammalian phylogenies. *Genome research* **20**, 110-121, doi:10.1101/gr.097857.109 (2010).
- Breiman, I. Random forests. *Machine Learning*. **45**, 5-32 (2001).
- Singleton, M. V. *et al.* Phevor combines multiple biomedical ontologies for accurate identification of disease-causing alleles in single individuals and small nuclear families. *American journal of human genetics* **94**, 599-610, doi:10.1016/j.ajhg.2014.03.010 (2014).
- Landrum, M. J. *et al.* ClinVar: improvements to accessing data. *Nucleic acids research* **48**, D835-D844, doi:10.1093/nar/gkz972 (2020).
- Online Mendelian Inheritance in Man, OMIM®. (McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University).
- 57 https://en.wikipedia.org/wiki/Bayes_factor.
- Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* **4**, 44-57, doi:10.1038/nprot.2008.211 (2009).
- Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* **581**, 434-443, doi:10.1038/s41586-020-2308-7 (2020).

- 60 Luo, C. *et al.* Superovulation strategies for 6 commonly used mouse strains. *J Am Assoc Lab Anim Sci* **50**, 471-478 (2011).
- Palu, R. A. S. & Chow, C. Y. Baldspot/ELOVL6 is a conserved modifier of disease and the ER stress response. *PLoS genetics* **14**, e1007557, doi:10.1371/journal.pgen.1007557 (2018).
- Wolfner, M. F. Battle and ballet: molecular interactions between the sexes in Drosophila. *J. Hered.* **100**, 399-410, doi:10.1093/jhered/esp013 (2009).
- Yang, X. *et al.* Gene variants identified by whole-exome sequencing in 33 French women with premature ovarian insufficiency. *Journal of assisted reproduction and genetics* **36**, 39-45, doi:10.1007/s10815-018-1349-4 (2019).
- Meduri, G. *et al.* Delayed puberty and primary amenorrhea associated with a novel mutation of the human follicle-stimulating hormone receptor: clinical, histological, and molecular studies. *The Journal of clinical endocrinology and metabolism* **88**, 3491-3498, doi:10.1210/jc.2003-030217 (2003).
- Touraine, P. *et al.* New natural inactivating mutations of the follicle-stimulating hormone receptor: correlations between receptor function and phenotype. *Molecular endocrinology* **13**, 1844-1854, doi:10.1210/mend.13.11.0370 (1999).
- Gurbuz, F. *et al.* Novel inactivating mutations of the DCAF17 gene in American and Turkish families cause male infertility and female subfertility in the mouse model. *Clin. Genet.* **93**, 853-859, doi:10.1111/cge.13183 (2018).
- Zhernakova, A., Withoff, S. & Wijmenga, C. Clinical implications of shared genetics and pathogenesis in autoimmune diseases. *Nat Rev Endocrinol* **9**, 646-659, doi:10.1038/nrendo.2013.161 (2013).
- Day, F. R. *et al.* Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. *Nature genetics* **47**, 1294-1303, doi:10.1038/ng.3412 (2015).
- Stolk, L. *et al.* Meta-analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways. *Nature genetics* **44**, 260-268, doi:10.1038/ng.1051 (2012).
- Wang, H. & Hoog, C. Structural damage to meiotic chromosomes impairs DNA recombination and checkpoint control in mammalian oocytes. *J Cell Biol* **173**, 485-495, doi:10.1083/jcb.200512077 (2006).
- Qin, Y. *et al.* CSB-PGBD3 Mutations Cause Premature Ovarian Failure. *PLoS genetics* **11**, e1005419, doi:10.1371/journal.pgen.1005419 (2015).
- Guzeloglu-Kayisli, O. *et al.* Embryonic poly(A)-binding protein (EPAB) is required for oocyte maturation and female fertility in mice. *Biochem J* **446**, 47-58, doi:10.1042/BJ20120467 (2012).
- Song, Z. H. *et al.* Germ cell-specific Atg7 knockout results in primary ovarian insufficiency in female mice. *Cell Death Dis.* **6**, e1589, doi:10.1038/cddis.2014.559 (2015).
- Pangas, S. A. *et al.* Intraovarian activins are required for female fertility. *Molecular endocrinology* **21**, 2458-2471, doi:10.1210/me.2007-0146 (2007).
- Tomic, D. *et al.* Ovarian follicle development requires Smad3. *Molecular endocrinology* **18**, 2224-2240, doi:10.1210/me.2003-0414 (2004).
- Ying, Y., Liu, X. M., Marble, A., Lawson, K. A. & Zhao, G. Q. Requirement of Bmp8b for the generation of primordial germ cells in the mouse. *Molecular endocrinology* **14**, 1053-1063, doi:10.1210/mend.14.7.0479 (2000).
- Myllymaa, S. *et al.* Inhibition of oocyte growth factors in vivo modulates ovarian folliculogenesis in neonatal and immature mice. *Reproduction* **139**, 587-598, doi:10.1530/REP-09-0391 (2010).
- Wang, J., Zhang, W., Jiang, H., Wu, B. L. & Primary Ovarian Insufficiency, C. Mutations in HFM1 in recessive primary ovarian insufficiency. *The New England journal of medicine* **370**, 972-974, doi:10.1056/NEJMc1310150 (2014).
- Robevska, G. *et al.* Functional characterization of novel NR5A1 variants reveals multiple complex roles in disorders of sex development. *Hum Mutat* **39**, 124-139, doi:10.1002/humu.23354 (2018).

- Camats, N. *et al.* Ten novel mutations in the NR5A1 gene cause disordered sex development in 46,XY and ovarian insufficiency in 46,XX individuals. *The Journal of clinical endocrinology and metabolism* **97**, E1294-1306, doi:10.1210/jc.2011-3169 (2012).
- Zeng, J. *et al.* Signatures of negative selection in the genetic architecture of human complex traits. *Nature genetics* **50**, 746-753, doi:10.1038/s41588-018-0101-4 (2018).
- Kasak, L. & Laan, M. Monogenic causes of non-obstructive azoospermia: challenges, established knowledge, limitations and perspectives. *Human genetics*, doi:10.1007/s00439-020-02112-y (2020).
- 83 Lascarez-Lagunas, L., Martinez-Garcia, M. & Colaiacovo, M. SnapShot: Meiosis Prophase I. *Cell* **181**, 1442-1442 e1441, doi:10.1016/j.cell.2020.04.038 (2020).
- Lei, L. & Spradling, A. C. Mouse oocytes differentiate through organelle enrichment from sister cyst germ cells. *Science* **352**, 95-99, doi:10.1126/science.aad2156 (2016).
- Fraile, J. M. *et al.* Loss of the deubiquitinase USP36 destabilizes the RNA helicase DHX33 and causes preimplantation lethality in mice. *The Journal of biological chemistry* **293**, 2183-2194, doi:10.1074/jbc.M117.788430 (2018).
- Lee, M. C., Skora, A. D. & Spradling, A. C. Identification of Genes Mediating Drosophila Follicle Cell Progenitor Differentiation by Screening for Modifiers of GAL4::UAS Variegation. *G3* (*Bethesda*) 7, 309-318, doi:10.1534/g3.116.036038 (2017).
- Sun, Y. et al. Molecular basis for the recognition of the human AAUAAA polyadenylation signal. Proceedings of the National Academy of Sciences of the United States of America 115, E1419-E1428, doi:10.1073/pnas.1718723115 (2018).
- Gomes Fernandes, M. *et al.* Human-specific subcellular compartmentalization of P-element induced wimpy testis-like (PIWIL) granules during germ cell development and spermatogenesis. *Human reproduction* **33**, 258-269, doi:10.1093/humrep/dex365 (2018).
- 89 Roovers, E. F. *et al.* Piwi proteins and piRNAs in mammalian oocytes and early embryos. *Cell Rep* **10**, 2069-2082, doi:10.1016/j.celrep.2015.02.062 (2015).
- Tan, M. *et al.* PIWIL3 Forms a Complex with TDRKH in Mammalian Oocytes. *Cells* **9**, doi:10.3390/cells9061356 (2020).
- Kuramochi-Miyagawa, S. *et al.* Mili, a mammalian member of piwi family gene, is essential for spermatogenesis. *Development* **131**, 839-849, doi:10.1242/dev.00973 (2004).
- Burns, K. H. *et al.* Roles of NPM2 in chromatin and nucleolar organization in oocytes and embryos. *Science* **300**, 633-636, doi:10.1126/science.1081813 (2003).
- Inoue, A., Ogushi, S., Saitou, M., Suzuki, M. G. & Aoki, F. Involvement of mouse nucleoplasmin 2 in the decondensation of sperm chromatin after fertilization. *Biol Reprod* **85**, 70-77, doi:10.1095/biolreprod.110.089342 (2011).
- Peng, H. *et al.* Valosin-containing protein is associated with maintenance of meiotic arrest in mouse oocytesdagger. *Biol Reprod* **100**, 963-970, doi:10.1093/biolre/ioy244 (2019).
- Beattie, R. *et al.* Mosaic Analysis with Double Markers Reveals Distinct Sequential Functions of Lg11 in Neural Stem Cells. *Neuron* **94**, 517-533 e513, doi:10.1016/j.neuron.2017.04.012 (2017).
- Liu, N. *et al.* A 21-bp indel within the LLGL1 gene is significantly associated with litter size in goat. *Anim. Biotechnol.*, 1-6, doi:10.1080/10495398.2019.1677682 (2019).
- 97 Higgs, M. R. *et al.* BOD1L Is Required to Suppress Deleterious Resection of Stressed Replication Forks. *Mol Cell* **59**, 462-477, doi:10.1016/j.molcel.2015.06.007 (2015).
- Hoek, A., Schoemaker, J. & Drexhage, H. A. Premature ovarian failure and ovarian autoimmunity. *Endocrine reviews* **18**, 107-134, doi:10.1210/edrv.18.1.0291 (1997).
- Frommer, L. & Kahaly, G. J. Autoimmune Polyendocrinopathy. *The Journal of clinical endocrinology and metabolism* **104**, 4769-4782, doi:10.1210/jc.2019-00602 (2019).
- Mandel, M., Gurevich, M., Pauzner, R., Kaminski, N. & Achiron, A. Autoimmunity gene expression portrait: specific signature that intersects or differentiates between multiple sclerosis and systemic lupus erythematosus. *Clin. Exp. Immunol.* **138**, 164-170, doi:10.1111/j.1365-2249.2004.02587.x (2004).


- Desai, S. *et al.* MCM8 and MCM9 Nucleotide Variants in Women with Primary Ovarian Insufficiency. *The Journal of clinical endocrinology and metabolism*, jc20162565, doi:10.1210/jc.2016-2565 (2016).
- Eskenazi, S. B., A.; Hugon-Rodin, J.; Plu-Bureau, G.; Gompel, A.; Catteau-Jonard, S.; Molina-Gomes, D.; Dewailly, D.; Dode, C.; Christin-Maitre, S.; Touraine, P. Next generation sequencing should be proposed to every woman with "idiopathic" premature ovarian insufficiency. *J Endocr Soc* (2021).
- 103 Vuillaumier-Barrot, S. *et al.* Expanding the Spectrum of PMM2-CDG Phenotype. *JIMD Rep* **5**, 123-125, doi:10.1007/8904_2011_114 (2012).
- Zhao, M., Feng, F., Chu, C., Yue, W. & Li, L. A novel EIF4ENIF1 mutation associated with a diminished ovarian reserve and premature ovarian insufficiency identified by whole-exome sequencing. *Journal of ovarian research* **12**, 119, doi:10.1186/s13048-019-0595-0 (2019).
- Perry, J. R. *et al.* DNA mismatch repair gene MSH6 implicated in determining age at natural menopause. *Human molecular genetics* **23**, 2490-2497, doi:10.1093/hmg/ddt620 (2014).
- 106 Chen, B. *et al.* Consanguineous familial study revealed biallelic FIGLA mutation associated with premature ovarian insufficiency. *Journal of ovarian research* **11**, 48, doi:10.1186/s13048-018-0413-0 (2018).
- Morita, Y. *et al.* Caspase-2 deficiency prevents programmed germ cell death resulting from cytokine insufficiency but not meiotic defects caused by loss of ataxia telangiectasia-mutated (Atm) gene function. *Cell Death Differ.* **8**, 614-620, doi:10.1038/sj.cdd.4400845 (2001).
- Pierce, S. B. *et al.* Mutations in LARS2, encoding mitochondrial leucyl-tRNA synthetase, lead to premature ovarian failure and hearing loss in Perrault syndrome. *American journal of human genetics* **92**, 614-620, doi:10.1016/j.ajhg.2013.03.007 (2013).
- 109 Chen, A. *et al.* Mutations in the mitochondrial ribosomal protein MRPS22 lead to primary ovarian insufficiency. *Human molecular genetics* **27**, 1913-1926, doi:10.1093/hmg/ddy098 (2018).
- Adelman, C. A. *et al.* HELQ promotes RAD51 paralogue-dependent repair to avert germ cell loss and tumorigenesis. *Nature* **502**, 381-384, doi:10.1038/nature12565 (2013).
- Renault, L. *et al.* BMPR1A and BMPR1B Missense Mutations Cause Primary Ovarian Insufficiency. *The Journal of clinical endocrinology and metabolism* **105**, doi:10.1210/clinem/dgz226 (2020).
- Norling, A. *et al.* Identification of a duplication within the GDF9 gene and novel candidate genes for primary ovarian insufficiency (POI) by a customized high-resolution array comparative genomic hybridization platform. *Human reproduction* **29**, 1818-1827, doi:10.1093/humrep/deu149 (2014).
- Qin, Y. *et al.* NOBOX homeobox mutation causes premature ovarian failure. *American journal of human genetics* **81**, 576-581, doi:10.1086/519496 (2007).
- Smirin-Yosef, P. *et al.* A Biallelic Mutation in the Homologous Recombination Repair Gene SPIDR Is Associated With Human Gonadal Dysgenesis. *The Journal of clinical endocrinology and metabolism* **102**, 681-688, doi:10.1210/jc.2016-2714 (2017).
- 115 Chrzanowska, K. H. *et al.* High prevalence of primary ovarian insufficiency in girls and young women with Nijmegen breakage syndrome: evidence from a longitudinal study. *The Journal of clinical endocrinology and metabolism* **95**, 3133-3140, doi:10.1210/jc.2009-2628 (2010).
- Wang, L. L. *et al.* Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. *Journal of the National Cancer Institute* **95**, 669-674, doi:10.1093/jnci/95.9.669 (2003).
- Siitonen, H. A. *et al.* The mutation spectrum in RECQL4 diseases. *Eur J Hum Genet* **17**, 151-158, doi:10.1038/ejhg.2008.154 (2009).
- Subramanian, G. N., Lavin, M. & Homer, H. A. Premature ovarian ageing following heterozygous loss of Senataxin. *Molecular human reproduction* **27**, doi:10.1093/molehr/gaaa080 (2021).


- Bakker, S. T. *et al.* Fancf-deficient mice are prone to develop ovarian tumours. *J. Pathol.* **226**, 28-39, doi:10.1002/path.2992 (2012).
- Huang, H. L. *et al.* Mutant ZP1 in familial infertility. *The New England journal of medicine* **370**, 1220-1226, doi:10.1056/NEJMoa1308851 (2014).
- Savitsky, K. *et al.* A single ataxia telangiectasia gene with a product similar to PI-3 kinase. *Science* **268**, 1749-1753, doi:10.1126/science.7792600 (1995).
- Weinberg-Shukron, A. *et al.* Essential Role of BRCA2 in Ovarian Development and Function. *The New England journal of medicine* **379**, 1042-1049, doi:10.1056/NEJMoa1800024 (2018).
- Xu, H., Beasley, M. D., Warren, W. D., van der Horst, G. T. & McKay, M. J. Absence of mouse REC8 cohesin promotes synapsis of sister chromatids in meiosis. *Dev. Cell* **8**, 949-961, doi:10.1016/j.devcel.2005.03.018 (2005).
- Bouilly, J. *et al.* Identification of Multiple Gene Mutations Accounts for a new Genetic Architecture of Primary Ovarian Insufficiency. *The Journal of clinical endocrinology and metabolism* **101**, 4541-4550, doi:10.1210/jc.2016-2152 (2016).
- Fouquet, B. *et al.* A homozygous FANCM mutation underlies a familial case of non-syndromic primary ovarian insufficiency. *Elife* **6**, doi:10.7554/eLife.30490 (2017).
- Fan, S. *et al.* Homozygous mutations in C14orf39/SIX6OS1 cause non-obstructive azoospermia and premature ovarian insufficiency in humans. *American journal of human genetics* **108**, 324-336, doi:10.1016/j.ajhg.2021.01.010 (2021).
- Gomez, H. L. *et al.* C14ORF39/SIX6OS1 is a constituent of the synaptonemal complex and is essential for mouse fertility. *Nat Commun* 7, 13298, doi:10.1038/ncomms13298 (2016).
- Fogli, A. *et al.* Ovarian failure related to eukaryotic initiation factor 2B mutations. *American journal of human genetics* **72**, 1544-1550, doi:10.1086/375404 (2003).
- Maddirevula, S. *et al.* A genomics approach to females with infertility and recurrent pregnancy loss. *Human genetics* **139**, 605-613, doi:10.1007/s00439-020-02143-5 (2020).
- Bekheirnia, M. R. *et al.* POLG mutation in a patient with cataracts, early-onset distal muscle weakness and atrophy, ovarian dysgenesis and 3-methylglutaconic aciduria. *Gene* **499**, 209-212, doi:10.1016/j.gene.2012.02.034 (2012).
- 131 Arora, H. et al. Bloom syndrome. Int. J. Dermatol. 53, 798-802, doi:10.1111/ijd.12408 (2014).
- Bashamboo, A. *et al.* Loss of Function of the Nuclear Receptor NR2F2, Encoding COUP-TF2, Causes Testis Development and Cardiac Defects in 46,XX Children. *American journal of human genetics* **102**, 487-493, doi:10.1016/j.ajhg.2018.01.021 (2018).
- Zangen, D. *et al.* XX ovarian dysgenesis is caused by a PSMC3IP/HOP2 mutation that abolishes coactivation of estrogen-driven transcription. *American journal of human genetics* **89**, 572-579, doi:10.1016/j.ajhg.2011.09.006 (2011).
- Alvaro Mercadal, B. *et al.* AMH mutations with reduced in vitro bioactivity are related to premature ovarian insufficiency. *Human reproduction* **30**, 1196-1202, doi:10.1093/humrep/dev042 (2015).
- Baronchelli, S. *et al.* Investigating the role of X chromosome breakpoints in premature ovarian failure. *Mol. Cytogenet.* **5**, 32, doi:10.1186/1755-8166-5-32 (2012).
- Ylikallio, E. *et al.* MCM3AP in recessive Charcot-Marie-Tooth neuropathy and mild intellectual disability. *Brain* **140**, 2093-2103, doi:10.1093/brain/awx138 (2017).
- Murray, A., Webb, J., Dennis, N., Conway, G. & Morton, N. Microdeletions in FMR2 may be a significant cause of premature ovarian failure. *Journal of medical genetics* **36**, 767-770, doi:10.1136/jmg.36.10.767 (1999).
- Pitman, J. L. *et al.* The fate of granulosa cells following premature oocyte loss and the development of ovarian cancers. *Int. J. Dev. Biol.* **56**, 949-958, doi:10.1387/ijdb.120144jp (2012).
- Moniruzzaman, M. & Miyano, T. KIT-KIT ligand in the growth of porcine oocytes in primordial follicles. *J Reprod Dev* **53**, 1273-1281, doi:10.1262/jrd.19107 (2007).


- Matikainen, T. *et al.* Caspase-3 gene knockout defines cell lineage specificity for programmed cell death signaling in the ovary. *Endocrinology* **142**, 2468-2480, doi:10.1210/endo.142.6.8078 (2001).
- Fotovati, A., Abu-Ali, S., Nakayama, K. & Nakayama, K. I. Impaired ovarian development and reduced fertility in female mice deficient in Skp2. *J. Anat.* **218**, 668-677, doi:10.1111/j.1469-7580.2011.01370.x (2011).
- Weng, K. A., Jeffreys, C. A. & Bickel, S. E. Rejuvenation of meiotic cohesion in oocytes during prophase I is required for chiasma maintenance and accurate chromosome segregation. *PLoS genetics* **10**, e1004607, doi:10.1371/journal.pgen.1004607 (2014).
- Boekhout, M. *et al.* REC114 Partner ANKRD31 Controls Number, Timing, and Location of Meiotic DNA Breaks. *Mol Cell* **74**, 1053-1068 e1058, doi:10.1016/j.molcel.2019.03.023 (2019).
- Papanikos, F. *et al.* Mouse ANKRD31 Regulates Spatiotemporal Patterning of Meiotic Recombination Initiation and Ensures Recombination between X and Y Sex Chromosomes. *Mol Cell* **74**, 1069-1085 e1011, doi:10.1016/j.molcel.2019.03.022 (2019).
- Juneja, S. C., Barr, K. J., Enders, G. C. & Kidder, G. M. Defects in the germ line and gonads of mice lacking connexin43. *Biol Reprod* **60**, 1263-1270, doi:10.1095/biolreprod60.5.1263 (1999).
- Iida, T. & Lilly, M. A. missing oocyte encodes a highly conserved nuclear protein required for the maintenance of the meiotic cycle and oocyte identity in Drosophila. *Development* **131**, 1029-1039, doi:10.1242/dev.01001 (2004).
- Hsieh, M. *et al.* Mice null for Frizzled4 (Fzd4-/-) are infertile and exhibit impaired corpora lutea formation and function. *Biol Reprod* **73**, 1135-1146, doi:10.1095/biolreprod.105.042739 (2005).
- Inagaki, A., Roset, R. & Petrini, J. H. Functions of the MRE11 complex in the development and maintenance of oocytes. *Chromosoma* **125**, 151-162, doi:10.1007/s00412-015-0535-8 (2016).
- Lipkin, S. M. *et al.* Meiotic arrest and aneuploidy in MLH3-deficient mice. *Nature genetics* **31**, 385-390, doi:10.1038/ng931 (2002).
- Lim, A. K. *et al.* The nuage mediates retrotransposon silencing in mouse primordial ovarian follicles. *Development* **140**, 3819-3825, doi:10.1242/dev.099184 (2013).
- Arafat, M. *et al.* Mutation in TDRD9 causes non-obstructive azoospermia in infertile men. *Journal of medical genetics* **54**, 633-639, doi:10.1136/jmedgenet-2017-104514 (2017).
- Aboura, A. *et al.* Array comparative genomic hybridization profiling analysis reveals deoxyribonucleic acid copy number variations associated with premature ovarian failure. *The Journal of clinical endocrinology and metabolism* **94**, 4540-4546, doi:10.1210/jc.2009-0186 (2009).
- Million Passe, C. M. *et al.* Loss of the protein NUPR1 (p8) leads to delayed LHB expression, delayed ovarian maturation, and testicular development of a sertoli-cell-only syndrome-like phenotype in mice. *Biol Reprod* **79**, 598-607, doi:10.1095/biolreprod.108.068304 (2008).
- Ratts, V. S., Flaws, J. A., Kolp, R., Sorenson, C. M. & Tilly, J. L. Ablation of bcl-2 gene expression decreases the numbers of oocytes and primordial follicles established in the post-natal female mouse gonad. *Endocrinology* **136**, 3665-3668, doi:10.1210/endo.136.8.7628407 (1995).
- de Boer, J. *et al.* Premature aging in mice deficient in DNA repair and transcription. *Science* **296**, 1276-1279, doi:10.1126/science.1070174 (2002).
- Xu, B. *et al.* Proliferating cell nuclear antigen (PCNA) regulates primordial follicle assembly by promoting apoptosis of oocytes in fetal and neonatal mouse ovaries. *PLoS One* **6**, e16046, doi:10.1371/journal.pone.0016046 (2011).
- Shindo, T. *et al.* ADAMTS-1: a metalloproteinase-disintegrin essential for normal growth, fertility, and organ morphology and function. *The Journal of clinical investigation* **105**, 1345-1352, doi:10.1172/JCI8635 (2000).
- Fischer-Vize, J. A., Rubin, G. M. & Lehmann, R. The fat facets gene is required for Drosophila eye and embryo development. *Development* **116**, 985-1000 (1992).


- Baumann, C., Viveiros, M. M. & De La Fuente, R. Loss of maternal ATRX results in centromere instability and aneuploidy in the mammalian oocyte and pre-implantation embryo. *PLoS genetics* **6**, e1001137, doi:10.1371/journal.pgen.1001137 (2010).
- Messiaen, S. *et al.* Rad54 is required for the normal development of male and female germ cells and contributes to the maintainance of their genome integrity after genotoxic stress. *Cell Death Dis.* **4**, e774, doi:10.1038/cddis.2013.281 (2013).
- Luo, M. *et al.* Protein Arginine Methyltransferase 6 Involved in Germ Cell Viability during Spermatogenesis and Down-Regulated by the Androgen Receptor. *Int. J. Mol. Sci.* **16**, 29467-29481, doi:10.3390/ijms161226186 (2015).
- Liu, S. S. *et al.* A Novel Regulatory Axis, CHD1L-MicroRNA 486-Matrix Metalloproteinase 2, Controls Spermatogonial Stem Cell Properties. *Molecular and cellular biology* **39**, doi:10.1128/MCB.00357-18 (2019).
- Iles, N., Rulten, S., El-Khamisy, S. F. & Caldecott, K. W. APLF (C2orf13) is a novel human protein involved in the cellular response to chromosomal DNA strand breaks. *Molecular and cellular biology* **27**, 3793-3803, doi:10.1128/MCB.02269-06 (2007).
- Bohgaki, T. *et al.* Genomic instability, defective spermatogenesis, immunodeficiency, and cancer in a mouse model of the RIDDLE syndrome. *PLoS genetics* **7**, e1001381, doi:10.1371/journal.pgen.1001381 (2011).
- Wang, H. *et al.* Inhibition of CDK7 bypasses spindle assembly checkpoint via premature cyclin B degradation during oocyte meiosis. *Biochim. Biophys. Acta* **1863**, 2993-3000, doi:10.1016/j.bbamcr.2016.09.020 (2016).
- Stern, H. R., Sefcikova, J., Chaparro, V. E. & Beuning, P. J. Mammalian DNA Polymerase Kappa Activity and Specificity. *Molecules* **24**, doi:10.3390/molecules24152805 (2019).
- Shapouri, F. *et al.* Tob1 is expressed in developing and adult gonads and is associated with the P-body marker, Dcp2. *Cell Tissue Res.* **364**, 443-451, doi:10.1007/s00441-015-2328-z (2016).
- 168 Consortium, G. T. The Genotype-Tissue Expression (GTEx) project. *Nature genetics* **45**, 580-585, doi:10.1038/ng.2653 (2013).
- Xu, C. *et al.* Crystal structure of human nuclear pore complex component NUP43. *FEBS Lett.* 589, 3247-3253, doi:10.1016/j.febslet.2015.09.008 (2015).
- Bui, K. H. *et al.* Integrated structural analysis of the human nuclear pore complex scaffold. *Cell* **155**, 1233-1243, doi:10.1016/j.cell.2013.10.055 (2013).
- Srivastava, S. *et al.* BRAT1 mutations present with a spectrum of clinical severity. *Am J Med Genet A* **170**, 2265-2273, doi:10.1002/ajmg.a.37783 (2016).
- Khan, T. N. *et al.* Mutations in NCAPG2 Cause a Severe Neurodevelopmental Syndrome that Expands the Phenotypic Spectrum of Condensinopathies. *American journal of human genetics* **104**, 94-111, doi:10.1016/j.ajhg.2018.11.017 (2019).
- 173 Chang, H. R. *et al.* Hypomorphic Mutations in TONSL Cause SPONASTRIME Dysplasia. *American journal of human genetics* **104**, 439-453, doi:10.1016/j.ajhg.2019.01.009 (2019).
- Burrage, L. C. *et al.* Bi-allelic Variants in TONSL Cause SPONASTRIME Dysplasia and a Spectrum of Skeletal Dysplasia Phenotypes. *American journal of human genetics* **104**, 422-438, doi:10.1016/j.ajhg.2019.01.007 (2019).
- Larsson, V. J., Jafferali, M. H., Vijayaraghavan, B., Figueroa, R. A. & Hallberg, E. Mitotic spindle assembly and gamma-tubulin localisation depend on the integral nuclear membrane protein Samp1. *J Cell Sci* **131**, doi:10.1242/jcs.211664 (2018).
- Wang, N., Zhang, P., Guo, X., Zhou, Z. & Sha, J. Hnrnpk, a protein differentially expressed in immature rat ovarian development, is required for normal primordial follicle assembly and development. *Endocrinology* **152**, 1024-1035, doi:10.1210/en.2010-0797 (2011).
- 177 Mendez, R. & Richter, J. D. Translational control by CPEB: a means to the end. *Nat. Rev. Mol. Cell Biol.* **2**, 521-529, doi:10.1038/35080081 (2001).


- 178 Catchpoole, D. *et al.* Mutation analysis of H19 and NAP1L4 (hNAP2) candidate genes and IGF2 DMR2 in Beckwith-Wiedemann syndrome. *Journal of medical genetics* **37**, 212-215, doi:10.1136/jmg.37.3.212 (2000).
- Dunwell, T. L. & Holland, P. W. H. A sister of NANOG regulates genes expressed in preimplantation human development. *Open Biol* **7**, doi:10.1098/rsob.170027 (2017).
- Zheng, Y. *et al.* The Seckel syndrome and centrosomal protein Ninein localizes asymmetrically to stem cell centrosomes but is not required for normal development, behavior, or DNA damage response in Drosophila. *Mol Biol Cell* **27**, 1740-1752, doi:10.1091/mbc.E15-09-0655 (2016).
- de Munnik, S. A. *et al.* Meier-Gorlin syndrome: growth and secondary sexual development of a microcephalic primordial dwarfism disorder. *Am J Med Genet A* **158A**, 2733-2742, doi:10.1002/ajmg.a.35681 (2012).
- Sun, X. *et al.* FancJ (Brip1) loss-of-function allele results in spermatogonial cell depletion during embryogenesis and altered processing of crossover sites during meiotic prophase I in mice. *Chromosoma* **125**, 237-252, doi:10.1007/s00412-015-0549-2 (2016).
- Li, J. *et al.* Differential display identifies overexpression of the USP36 gene, encoding a deubiquitinating enzyme, in ovarian cancer. *Int. J. Med. Sci.* **5**, 133-142, doi:10.7150/ijms.5.133 (2008).
- Chapman, K. M. *et al.* Linking spermatid ribonucleic acid (RNA) binding protein and retrogene diversity to reproductive success. *Mol. Cell. Proteomics* **12**, 3221-3236, doi:10.1074/mcp.M113.030585 (2013).
- Virant-Klun, I., Leicht, S., Hughes, C. & Krijgsveld, J. Identification of Maturation-Specific Proteins by Single-Cell Proteomics of Human Oocytes. *Mol. Cell. Proteomics* **15**, 2616-2627, doi:10.1074/mcp.M115.056887 (2016).
- Celichowski, P. *et al.* "Positive Regulation of RNA Metabolic Process" Ontology Group Highly Regulated in Porcine Oocytes Matured In Vitro: A Microarray Approach. *Biomed Res Int* **2018**, 2863068, doi:10.1155/2018/2863068 (2018).




















Double Strand Break Repair Crossovers Dissociation of Holliday Junctions & Resolution

BRCA1	BLM	BRIP1	RUVBL2
BRCA2	FANCA	MCM9	MIOS
RAD50	FANCD2	HELQ	APLF
RAD51	MLH3	RECQL4	RNF168
ATM	P1F1	FANCF	TONSL